🔗

Mappings

MONDO

MONDO:0014328 developmental and epileptic encephalopathy, 19

👪

Inheritance

1

Autosomal dominant (typically de novo) HP:0000006

DEE19 is inherited in an autosomal dominant manner, but affected individuals in the encephalopathic range almost always carry a de novo heterozygous variant rather than an inherited one. Inherited transmission does occur and is concentrated at the milder end of the spectrum: in the largest functional cohort, the two inherited transmembrane-domain variants were specifically noted as the exception to the rule that transmembrane variants cause severe phenotypes. ClinGen's Epilepsy Gene Curation Expert Panel classifies the GABRA1-epilepsy relationship as Definitive with autosomal dominant inheritance.

Autosomal dominant inheritance

Show evidence (3 references)

PMID:26918889 SUPPORT Human Clinical

"We identified five de novo missense GABRA1 mutations in six unrelated patients."

Documents de novo occurrence of GABRA1 missense variants across six unrelated patients with early-onset epileptic encephalopathy, supporting a dominant, predominantly de novo mechanism.

CGGV:assertion_60478d36-384e-4246-ba8a-730755d6f216-2024-09-03T170000.000Z SUPPORT Other

ClinGen Epilepsy Gene Curation Expert Panel records the GABRA1-epilepsy relationship as Definitive with autosomal dominant inheritance.

PMID:37606373 SUPPORT Human Clinical

"In the transmembrane domain, we observed 4 missense variants with GoF effect and 5 variants with LoF effect, of which 2 were inherited."

Records that inherited transmission occurs but is the exception among transmembrane-domain variants, which are otherwise the severe, predominantly de novo group.

?

Discussions and Knowledge Gaps

1

Do the available Gabra1 mouse models actually model DEE19, given that both carry alleles from the mild end of the GABRA1 spectrum and both produce absence epilepsy rather than an infantile encephalopathy?

HUMAN MODEL MISMATCH gabra1_models_lack_gof_encephalopathy_allele

Attached to

animal_models#Gabra1 heterozygous knockout mouse animal_models#Gabra1 A322D knock-in mouse pathophysiology#Gain-of-Function Shift in GABA Sensitivity and Desensitization

Both committed animal models are informative for the shared network mechanism but neither reproduces the disease this entry curates. The heterozygous knockout models dosage loss, while most human DEE19 variants are missense; the A322D knock-in carries a juvenile myoclonic epilepsy allele from the opposite end of the severity spectrum. Neither models the gain-of-function transmembrane variants that produce the most severe human phenotype, and neither shows developmental regression or encephalopathy. The mismatch is mechanistically meaningful because the human genotype-phenotype data show severity is determined by variant class and structural position — exactly the dimension the existing models do not sample.

Proposed experiments

Knock-in mouse carrying a gain-of-function transmembrane-helix GABRA1 variant

gabra1_gof_knockin_severity_comparison

Generate a knock-in mouse carrying a human DEE19 gain-of-function transmembrane-helix variant (for example the TM3 A332V allele) and characterize seizure phenotype, developmental trajectory and EEG against both wild-type and the existing A322D line.

Would support

pathophysiology#Gain-of-Function Shift in GABA Sensitivity and Desensitization

Supporting outcome

The gain-of-function knock-in shows earlier seizure onset, a more severe and refractory seizure phenotype, and measurable developmental impairment relative to the A322D loss-of-function line, reproducing the human severity ordering.

Refuting outcome

The gain-of-function knock-in produces a phenotype no more severe than the A322D line, indicating that the human severity difference is not attributable to the receptor-level functional class alone.

⚙

Pathophysiology

9

GABRA1 Variant and Alpha-1 Subunit Dysfunction

The initiating lesion is a heterozygous, typically de novo variant in GABRA1, which encodes the alpha-1 subunit of the GABA-A receptor. GABA-A receptors are pentameric ligand-gated chloride channels that mediate most fast inhibitory neurotransmission in the mature brain; alpha-1 is the most abundant alpha subunit in the adult brain, and its expression rises steeply over the first postnatal years as it replaces the alpha-2/alpha-3 subunits that predominate prenatally. That developmental expression switch is why a variant restricted to this subunit produces an epilepsy of infancy and early childhood. Most pathogenic variants are missense and cluster either in the extracellular domain or in the pore-forming transmembrane helices, and this structural position — not merely the presence of a variant — determines phenotype severity.

Neuron CL:0000540

Regulation of Membrane Potential GO:0042391 ⚠ ABNORMAL Chemical Synaptic Transmission GO:0007268 ⚠ ABNORMAL

GABA-gated chloride ion channel activity of the alpha-1-containing receptor GO:0022851 ⚠ ABNORMAL

Downstream

Loss-of-Function Reduction in GABA-A Receptor Current Variants in the extracellular domain, the small transmembrane loops, and a subset of transmembrane-helix positions reduce GABA-gated current.

Gain-of-Function Shift in GABA Sensitivity and Desensitization A distinct class of variants in the pore-forming transmembrane helices increases rather than decreases GABA sensitivity.

Show evidence (3 references)

PMID:24623842 SUPPORT Human Clinical

"We detected disease-causing mutations in 2 novel genes for Dravet syndrome, with mutations in GABRA1 in 4 cases and STXBP1 in 3."

Establishes GABRA1 variants as a cause of severe infantile-onset epileptic encephalopathy, identified by exome sequencing in SCN1A-negative patients.

PMID:26918889 SUPPORT Human Clinical

"Our study suggests that de novo GABRA1 mutations can cause early onset epileptic encephalopathies, including Ohtahara syndrome and West syndrome."

Directly attributes early-onset epileptic encephalopathy, including the severe electroclinical syndromes of infancy, to de novo GABRA1 variants.

PMID:32047208 SUPPORT In Vitro

"The expression of alpha1 is very low in pre- and perinatal rodent brain, but it increases dramatically after birth in all brain regions"

Supports the developmental-expression rationale for why an alpha-1-specific lesion manifests as an epilepsy of infancy and early childhood rather than prenatally.

Loss-of-Function Reduction in GABA-A Receptor Current

The most frequently demonstrated functional consequence of a pathogenic GABRA1 variant is a reduction in GABA-evoked chloride current through receptors containing the mutant subunit. Patch-clamp characterization of the de novo R214C variant showed the reduction arises from two separable defects: a shortened single-channel open time, and a fall in the amount of receptor present at all. Loss of function is the effect seen in the extracellular-domain variants and in a subset of transmembrane variants.

Genetic context GABRA1 hgnc:4075 allele_type: missense variant_origin: DE_NOVO zygosity: HETEROZYGOUS functional_impact_category: LOSS_OF_FUNCTION

Missense variants in the extracellular domain and small transmembrane loops (for example p.Arg214Cys) are uniformly loss-of-function. Clinically they produce a more homogeneous and milder picture — infantile-onset focal seizures with fever sensitivity, posterior epileptiform discharges and mild cognitive impairment — with a generally favorable outcome. A subset of pore-forming transmembrane-helix variants is also loss-of-function but clinically more severe.

Chloride Transmembrane Transport GO:1902476 ↓ DECREASED

GABA-gated chloride ion channel activity GO:0022851 ↓ DECREASED

Downstream

Impaired Receptor Trafficking and Surface Expression Part of the current reduction is not a gating defect at all but a failure to deliver and retain receptor at the cell surface.

Impaired GABAergic Inhibitory Neurotransmission Reduced chloride current through synaptic GABA-A receptors weakens fast inhibitory synaptic transmission.

Show evidence (4 references)

PMID:31707987 SUPPORT In Vitro

"We found that the GABRA1 (R214C) variant decreased whole-cell GABA-evoked currents by reducing single channel open time and both surface and total GABAA receptor expression levels."

Directly measures reduced GABA-evoked current in a de novo encephalopathy-associated variant and identifies the two mechanisms producing it.

PMID:27521439 SUPPORT In Vitro

"Functional analysis of 4 selected mutations was performed using the Xenopus laevis oocyte expression system."

Records the heterologous expression system in which the loss-of-function effect of patient GABRA1 variants was established.

PMID:37606373 SUPPORT Human Clinical

"A homogenous phenotype with mild cognitive impairment and infantile onset epilepsy (focal seizures, fever sensitivity, and electroencephalographic posterior epileptiform discharges) was described for variants in the extracellular domain and the small transmembrane loops. These variants displayed..."

Ties extracellular-domain localization to the loss-of-function effect and to the milder clinical subgroup, establishing where this node's mechanism sits on the severity spectrum.

+ 1 more reference

Impaired Receptor Trafficking and Surface Expression

A recurring cellular consequence of GABRA1 variants is that mutant subunits fail to reach or be retained at the neuronal surface, so that even intrinsically functional receptor is under-represented at the synapse. Quantification of the R214C variant showed both surface and total receptor protein were reduced, indicating loss of the subunit pool as well as mislocalization. This is a distinct mechanism from altered channel gating, and it is the arm that pharmacological chaperone strategies target.

Neuron CL:0000540

Downstream

Impaired GABAergic Inhibitory Neurotransmission Fewer GABA-A receptors at the synapse means less inhibitory conductance available per released quantum of GABA.

Show evidence (1 reference)

PMID:31707987 SUPPORT In Vitro

"We found that the GABRA1 (R214C) variant decreased whole-cell GABA-evoked currents by reducing single channel open time and both surface and total GABAA receptor expression levels."

Establishes reduced surface and total receptor expression as a measured consequence of an encephalopathy-associated GABRA1 variant.

Gain-of-Function Shift in GABA Sensitivity and Desensitization

A functionally opposite class of GABRA1 variants, localized to the pore-forming transmembrane helices, increases the apparent potency of GABA and alters receptor desensitization without reducing receptor expression or trafficking. The de novo A332V variant in transmembrane helix 3 showed unchanged protein levels, normal assembly and normal forward trafficking, but a significant left shift in apparent GABA potency. Counterintuitively it is this gain-of-function group, not the loss-of-function group, that carries the most severe early-onset neurodevelopmental phenotype — a pattern also seen in the paralogous GABRB3 encephalopathy, and one that matters clinically because it inverts the expected direction of GABAergic pharmacotherapy.

Genetic context GABRA1 hgnc:4075 allele_type: missense variant_origin: DE_NOVO zygosity: HETEROZYGOUS functional_impact_category: GAIN_OF_FUNCTION

Missense variants in the pore-forming transmembrane helices (for example p.Ala332Val in TM3) increase apparent GABA potency without reducing receptor expression or trafficking. This is the most severe class, associated with early infantile developmental and epileptic encephalopathy.

GABA-gated chloride ion channel activity GO:0022851 ⇑ GAIN OF FUNCTION

Downstream

Disrupted Excitation-Inhibition Balance in the Developing Brain Altered GABA sensitivity and desensitization kinetics disturb the timing and magnitude of inhibition during a developmental window in which GABAergic signaling also shapes circuit maturation, rather than simply increasing useful inhibition.

Show evidence (3 references)

PMID:32047208 SUPPORT In Vitro

"In vitro assessment revealed unchanged protein levels, regular assembly and forward trafficking to the cell surface. On the functional level a significant left shift of the apparent GABA potency in two-electrode voltage clamp electrophysiology experiments was observed, as well as changes in the..."

Directly measures increased GABA potency and altered desensitization with preserved trafficking, defining the gain-of-function mechanism as distinct from the loss-of-function/trafficking arm.

PMID:37606373 SUPPORT Human Clinical

"GoF variants were associated with severe early onset neurodevelopmental disorders, including early infantile developmental and epileptic encephalopathy."

Establishes that the gain-of-function class maps onto the severe early-onset encephalopathic phenotype this entry curates.

PMID:32047208 SUPPORT In Vitro

"Here we study functional consequences of a novel de novo missense GABRA1 variant, p.(Ala332Val), identified through exome sequencing in an individual affected by early-onset syndromic epileptic encephalopathy. The variant is localised within the transmembrane domain helix 3 (TM3)"

Identifies the specific de novo transmembrane-helix missense variant in a patient with early-onset epileptic encephalopathy and locates it structurally, grounding this gain-of-function node.

Impaired GABAergic Inhibitory Neurotransmission

Loss of alpha-1-containing GABA-A receptor function at the synapse weakens fast phasic inhibition. In the heterozygous Gabra1 mouse, this is directly measurable as a substantial reduction in the peak amplitude and frequency of miniature inhibitory postsynaptic currents in the ventrobasal thalamus, with no compensatory increase in tonic GABA-A current — establishing that the deficit is specifically in phasic synaptic inhibition. Compensation by other alpha subunits is region-specific and incomplete.

GABAergic Neuron CL:0000617

GABA Signaling Pathway GO:0007214 ↓ DECREASED

Animal models

Gabra1 heterozygous knockout mouse Mouse recapitulates Directly measures the loss of phasic GABAergic inhibition produced by alpha-1 subunit loss in an intact thalamic circuit.

Downstream

Disrupted Excitation-Inhibition Balance in the Developing Brain Weakened inhibition shifts the net balance of excitation and inhibition toward excitation.

Show evidence (2 references)

PMID:25447232 SUPPORT Model Organism

"In addition, heterozygous α1 subunit deletion substantially reduced miniature inhibitory postsynaptic current (mIPSC) peak amplitudes and frequency in VB."

Measures the physiological consequence of alpha-1 loss as a reduction in phasic inhibitory synaptic currents in an intact circuit.

PMID:25447232 SUPPORT Model Organism

"However, there was no change in the expression of the extrasynaptic α4 or δ subunits in VB and, unlike other models of absence epilepsy, no change in tonic GABAAR currents."

Directly reports the absence of any change in tonic GABA-A current, establishing that the deficit driving seizures in alpha-1 haploinsufficiency is in phasic rather than tonic inhibition.

Disrupted Excitation-Inhibition Balance in the Developing Brain

Whether inhibition is reduced (loss-of-function variants) or its timing and sensitivity are distorted (gain-of-function variants), the shared consequence is a shift in the balance of excitation and inhibition in maturing cortical and thalamocortical circuits. The developmental timing matters: alpha-1 expression rises steeply over the first postnatal years, so the imbalance is imposed on circuits that are still being assembled, and GABAergic signaling is itself one of the signals shaping that assembly. This is why the outcome is an encephalopathy — a disorder of development — rather than seizures alone.

GABAergic Neuron CL:0000617

GABA Signaling Pathway GO:0007214 ⚠ ABNORMAL

Downstream

Neuronal Hyperexcitability and Thalamocortical Hypersynchrony Net excitatory bias produces a hyperexcitable, hypersynchronous network state.

Show evidence (1 reference)

PMID:32047208 SUPPORT In Vitro

"GABA has multiple functions during neurodevelopment, such as regulating neuronal cell proliferation, maturation and migration"

Supports the claim that GABAergic signaling is a developmental signal, so that disturbing it during circuit assembly produces a developmental disorder and not only seizures.

Neuronal Hyperexcitability and Thalamocortical Hypersynchrony

The excitation-inhibition shift converts into a hyperexcitable network that fires excessively and in synchrony. In the Gabra1 heterozygous mouse the ventrobasal thalamus is disinhibited by the loss of phasic GABAergic current, while the reticular nucleus paradoxically shows prolonged phasic currents — a partial compensation. In the Gabra1 A322D knock-in, EEG connectivity across sensorimotor cortex rises at the onset of both absence and myoclonic seizures, with somatosensory cortex leading motor cortex, showing that distinct seizure types in the same animal recruit overlapping cortical networks.

Neuron CL:0000540

Action Potential GO:0001508 ↑ INCREASED

Animal models

Gabra1 A322D knock-in mouse Mouse partially recapitulates Reproduces the network hypersynchrony step, showing increased EEG connectivity at seizure onset with somatosensory cortex leading motor cortex.

Downstream

Seizure Generation in the Developing Brain Hypersynchronous network discharges manifest clinically as seizures.

Show evidence (2 references)

PMID:25447232 SUPPORT Model Organism

"In addition, heterozygous loss of α1 subunit disinhibits VB by substantially reducing phasic GABAergic currents and surprisingly, it also increases nRT inhibition by prolonging phasic currents."

Localizes the disinhibition produced by alpha-1 loss to a specific thalamic node of the seizure-generating network.

PMID:27573707 SUPPORT Model Organism

"EEG connectivity among all electrode pairs increased at the onset of both SWDs and myoclonic seizures."

Measures the rise in network synchrony at seizure onset in a Gabra1 knock-in mouse, supporting hypersynchrony as the central effector step.

Seizure Generation in the Developing Brain

Hypersynchronous discharges manifest as recurrent seizures, typically beginning in the first year of life. The seizure repertoire is broad rather than syndrome-specific: focal and generalized tonic-clonic seizures, typical and atypical absences, myoclonic and atonic seizures, and epileptic spasms are all reported, and individual patients commonly have several types. In the most severe presentations the electroclinical picture is that of a recognized encephalopathy of infancy — West syndrome with hypsarrhythmia, or Ohtahara syndrome.

Neuron CL:0000540

Downstream

Drug-Resistant Epilepsy with Developmental Impairment Ongoing seizures and the underlying inhibitory deficit together produce the chronic encephalopathic outcome.

Infantile-onset epilepsy Seizure generation in the first year of life is what presents clinically as infantile-onset epilepsy.

Bilateral tonic-clonic seizure Generalized hypersynchronous discharge manifests as the tonic-clonic seizure type, the most common in the GABRA1 cohort.

Myoclonic seizure Brief generalized discharges manifest as myoclonic seizures.

Epileptic spasm In the severe transmembrane-variant group, seizure generation in the immature brain takes the form of epileptic spasms.

Fever-sensitive seizures Fever lowers the threshold for seizure generation, producing the fever-precipitated seizures prominent in the loss-of-function group.

EEG with photoparoxysmal response The hyperexcitable network responds pathologically to photic stimulation, recorded as a photoparoxysmal EEG response.

Hypsarrhythmia The severely disorganized interictal state of the epileptic infant brain is recorded as hypsarrhythmia.

Show evidence (2 references)

PMID:37606373 SUPPORT Human Clinical

"Seizure types included focal and generalized tonic–clonic seizures, typical and atypical absences, myoclonic and atonic seizures, and epileptic spasms."

Enumerates the seizure repertoire produced by GABRA1 variants in a 27-individual cohort, supporting the breadth of this effector step.

PMID:26918889 SUPPORT Human Clinical

"p.P260L, p.M263T, and p.M263I in transmembrane spanning domain 1 (TM1) were identified in three unrelated patients with West syndrome and a patient with Ohtahara syndrome, respectively"

Anchors the most severe electroclinical syndromes of infancy to specific de novo transmembrane-domain GABRA1 variants.

Drug-Resistant Epilepsy with Developmental Impairment

The clinical endpoint is chronic epilepsy accompanied by developmental delay or intellectual disability, which affects the large majority of individuals with a pathogenic GABRA1 variant. Outcome tracks the functional class of the variant: extracellular-domain loss-of-function variants generally have a favorable outcome, with most patients becoming seizure-free on monotherapy after an initial stormy phase, whereas transmembrane-helix variants — particularly gain-of-function ones — produce refractory seizures, regression and severe impairment. Additional neurodevelopmental and movement problems (autism spectrum disorder, ADHD and behavioral disturbance, ataxia, tremor, dystonia) are common.

Neuron CL:0000540

Downstream

Global developmental delay and intellectual disability The developmental arm of the encephalopathy presents as delay or intellectual disability, affecting 88% of the cohort.

Developmental regression In the most severely affected patients the developmental course is not merely delayed but regressive, with loss of acquired skills.

Autism spectrum disorder Autism spectrum disorder is part of the broader neurodevelopmental burden accompanying the encephalopathy.

Behavioral disturbance and ADHD Behavioral disturbance and attention-deficit/hyperactivity disorder are a common non-cognitive neurodevelopmental accompaniment, reported at the same rate as the movement-disorder group in the source cohort.

Ataxia and movement disorder Movement disorders accompany the encephalopathy in about a third of individuals.

Show evidence (2 references)

PMID:37606373 SUPPORT Human Clinical

"Most individuals (21/24, 88%) had various degrees of ID or developmental delay."

Quantifies the developmental component of the encephalopathy across the cohort, establishing this consequence node.

PMID:37606373 SUPPORT Human Clinical

"Generally, variants in the transmembrane helices cause more severe phenotypes, in particular GoF variants."

Supports the claim that outcome severity tracks the structural position and functional class of the variant.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

12

Infantile-onset epilepsy VERY_FREQUENT Neurological HP:0001250

Onset: INFANTILE

Show evidence (2 references)

PMID:27521439 SUPPORT Human Clinical

"In the epileptic encephalopathy group, the patients had seizures beginning between the first day of life and 15 months, with a mean of 7 months."

Directly reports the age-at-onset distribution in the encephalopathic subgroup this entry curates.

PMID:37606373 SUPPORT Human Clinical

"Epilepsy was diagnosed in 23 of 24 (96%) subjects,"

Quantifies epilepsy frequency across the GABRA1 cohort, supporting the VERY_FREQUENT band.

Bilateral tonic-clonic seizure FREQUENT Neurological HP:0002069

Show evidence (1 reference)

PMID:27521439 SUPPORT Human Clinical

"Predominant seizure types in all patients were tonic-clonic in 9 participants (56%) and myoclonic seizures in 5 (31%)."

Quantifies tonic-clonic seizures as the predominant seizure type in the GABRA1 cohort.

Myoclonic seizure FREQUENT Neurological HP:0032794

Show evidence (1 reference)

PMID:27521439 SUPPORT Human Clinical

"Myoclonic and tonic-clonic seizures with pathologic response to photic stimulation are common and shared features in both mild and severe phenotypes."

Identifies myoclonic seizures as a common and cross-spectrum feature of GABRA1-related epilepsy.

Epileptic spasm OCCASIONAL Neurological HP:0011097

Show evidence (2 references)

PMID:26918889 SUPPORT Human Clinical

"p.P260L, p.M263T, and p.M263I in transmembrane spanning domain 1 (TM1) were identified in three unrelated patients with West syndrome and a patient with Ohtahara syndrome, respectively"

Documents West syndrome, whose defining seizure type is epileptic spasms, in patients with de novo GABRA1 variants.

PMID:37606373 SUPPORT Human Clinical

"presented with infantile spasms, developmental regression, and hypsarrhythmia at the age of 5 months."

A specific patient with a transmembrane-domain variant presenting with the full West syndrome triad.

Global developmental delay and intellectual disability VERY_FREQUENT Neurological HP:0001263

Show evidence (1 reference)

PMID:37606373 SUPPORT Human Clinical

"Most individuals (21/24, 88%) had various degrees of ID or developmental delay."

Quantifies developmental delay/intellectual disability at 88% of the cohort, supporting the VERY_FREQUENT band.

Developmental regression OCCASIONAL Neurological HP:0002376

Show evidence (1 reference)

PMID:37606373 SUPPORT Human Clinical

"presented with infantile spasms, developmental regression, and hypsarrhythmia at the age of 5 months."

Documents developmental regression as part of the severe transmembrane-variant presentation.

Hypsarrhythmia OCCASIONAL Neurological HP:0002521

Show evidence (1 reference)

PMID:37606373 SUPPORT Human Clinical

"presented with infantile spasms, developmental regression, and hypsarrhythmia at the age of 5 months."

Directly documents hypsarrhythmia in a patient with a de novo GABRA1 transmembrane-domain variant.

EEG with photoparoxysmal response FREQUENT Neurological HP:0010852

Show evidence (1 reference)

PMID:27521439 SUPPORT Human Clinical

"EEG showed a generalized photoparoxysmal response in 6 patients (37%)."

Directly quantifies the photoparoxysmal EEG response in the GABRA1 cohort.

Fever-sensitive seizures FREQUENT Neurological HP:0002373

Show evidence (1 reference)

PMID:37606373 SUPPORT Human Clinical

"Fever sensitivity was reported in 9 of 10 (90%)"

Quantifies fever sensitivity in the extracellular-domain subgroup. The 90% is that subgroup's rate, not the cohort's. Summing the Table 2 row across all variant classes (9/10, 1/3, 0/2, 3/4, 0/2) gives 13 of the 21 individuals with fever data, about 62%, which is the band recorded here.

Autism spectrum disorder OCCASIONAL Neurological HP:0000717

Show evidence (1 reference)

PMID:37606373 SUPPORT Human Clinical

"autism spectrum disorder (ASD; 5/24, 21%)"

Records autism spectrum disorder in 5 of 24 individuals (21%) in the GABRA1 cohort.

Behavioral disturbance and ADHD OCCASIONAL Neurological HP:0007018

Show evidence (1 reference)

PMID:37606373 SUPPORT Human Clinical

"and behavioral disturbances or attention-de ﬁcit/ hyperactivity disorder (ADHD; 7/24, 29%)."

Quantifies behavioral disturbance and ADHD at 7 of 24 individuals (29%) in the GABRA1 cohort. The quoted text preserves the ligature and spacing artifacts present in the cached source.

Ataxia and movement disorder OCCASIONAL Neurological HP:0001251

Show evidence (1 reference)

PMID:37606373 SUPPORT Human Clinical

"including ataxia, poor coor dination, tremor, dystonia, and cerebral palsy, were also reported (7/24, 29%)."

Quantifies the movement-disorder burden in the GABRA1 cohort. The quoted text preserves the spacing artifact present in the cached source.

🧬

Genetic Associations

1

GABRA1 (GABRA1 (5q34) encodes the alpha-1 subunit of the GABA-A receptor. Heterozygous, typically de novo, predominantly missense variants cause developmental and epileptic encephalopathy 19. The variant landscape is organized by structural position within the subunit: extracellular-domain and small-transmembrane-loop variants are loss-of-function and produce a milder epilepsy with generally favorable outcome, whereas pore-forming transmembrane-helix variants — which may be either loss-of-function or gain-of-function — produce the severe encephalopathic phenotype, the gain-of-function subset being the most severe. ClinGen classifies the GABRA1-epilepsy relationship as Definitive.)

Gene: GABRA1 hgnc:4075 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Autosomal dominant (typically de novo)

Show evidence (3 references)

CGGV:assertion_60478d36-384e-4246-ba8a-730755d6f216-2024-09-03T170000.000Z SUPPORT Other

ClinGen Epilepsy Gene Curation Expert Panel classifies the GABRA1-epilepsy gene-disease relationship as Definitive.

PMID:37606373 SUPPORT Human Clinical

"Genetic and electroclinical data of 27 individuals (22 unrelated and 2 families) harboring 20 different GABRA1 variants were collected and accompanied by functional analysis of 19 variants."

Establishes the size and design of the cohort underpinning the structure-function organization of the GABRA1 variant landscape.

PMID:24623842 SUPPORT Human Clinical

"We show that GABRA1 and STXBP1 make a significant contribution to Dravet syndrome after SCN1A abnormalities have been excluded."

Quantifies GABRA1's contribution to severe infantile epileptic encephalopathy in the SCN1A-negative population.

💊

Medical Actions

5

Broad-spectrum antiseizure pharmacotherapy

Action: Pharmacotherapy NCIT:C15986

Agent: valproic acid CHEBI:39867 levetiracetam CHEBI:6437

Platform: Small molecule

Antiseizure medication is the mainstay of management. Response is strongly stratified by variant class: in the extracellular-domain loss-of-function group, most patients become seizure-free on monotherapy after an initial stormy phase, whereas antiseizure medications are reported to be ineffective in patients with gain-of-function variants and severe epilepsy. Within the loss-of-function group the choice of agent appears to be gene-specific, with levetiracetam identified as the most effective drug for GABRA1 (as against valproate for the paralogous GABRB3). This is a cohort observation rather than a trial result, so it is a treatment lead and not an established first-line recommendation.

Mechanism Target:

Neuronal Hyperexcitability and Thalamocortical Hypersynchrony — Antiseizure medications act on the hyperexcitable, hypersynchronous network state rather than on the receptor lesion itself.

Show evidence (3 references)

PMID:37606373 SUPPORT Human Clinical

"6 of 11 (55%) subjects became seizure-free on monotherapy at an age ranging from 9 months to 6 years,"

Reports the favorable monotherapy response in the milder extracellular-domain subgroup, establishing that variant class predicts treatment response.

PMID:37606373 REFUTE Human Clinical

"Conversely, ASMs are ineffective in patients with GoF GABRA1 variants with severe epilepsy, and this was also observed for individuals harboring pathogenic GABRB3 variants located in the transmembrane domain."

Refutes any claim that broad-spectrum antiseizure pharmacotherapy is reliably effective across DEE19, by stating directly that antiseizure medications are ineffective in the gain-of-function group with severe epilepsy — the group this entry is scoped to.

PMID:37606373 SUPPORT Human Clinical

"Interestingly the most effective treatment for LoF variants in GABRA1 and GABRB3 varies, with LEV identi ﬁed for GABRA1 individuals versus VPA in GABRB3."

Identifies levetiracetam as the most effective agent in the loss-of-function group specifically for GABRA1, distinguishing it from the paralogous GABRB3 where valproate is preferred. The quoted text preserves the ligature artifact present in the cached source.

Corticotropin and corticosteroid therapy for infantile spasms

Action: Pharmacotherapy NCIT:C15986

Agent: corticotropin CHEBI:3892 prednisolone CHEBI:8378

Platform: Peptide

Where the presentation is West syndrome with infantile spasms, the standard spasm-directed treatments apply. A GABRA1 transmembrane-variant patient whose spasms had failed conventional antiseizure medication responded to adrenocorticotropic hormone and prednisolone and achieved seizure freedom, although EEG abnormalities persisted.

Mechanism Target:

Seizure Generation in the Developing Brain — Hormonal therapy suppresses the epileptic spasms phenotype rather than correcting the receptor defect.

Show evidence (2 references)

PMID:37606373 SUPPORT Human Clinical

"Infantile spasms were responsive to adrenocorticotropic hormone"

Documents response of GABRA1-associated infantile spasms to adrenocorticotropic hormone in a specific patient. The sentence continues "and prednisolone" in the source, but that word is split across a line-break hyphen in the cached PDF extraction and so cannot be quoted without corrupting it; prednisolone is therefore carried in the description and therapeutic_agent rather than in this quote.

PMID:37606373 SUPPORT Human Clinical

"and the patient achieved seizure freedom, despite the persistence of almost continuous EEG abnormalities,"

Records the outcome of that hormonal therapy — clinical seizure freedom despite persisting EEG abnormality — which is why this treatment is described as suppressing the spasms phenotype rather than correcting the receptor defect.

Variant-specific pharmacological rescue (investigational)

Action: Pharmacotherapy NCIT:C15986

Agent: verapamil CHEBI:9948

Platform: Small molecule

Because different GABRA1 variants disable the receptor by different mechanisms, agents that address the specific defect are being explored. For the trafficking-deficient R214C variant, 24-hour verapamil treatment fully restored mutant receptor function in vitro, primarily by increasing channel open time, whereas diazepam and insulin produced only partial restoration. This is an in-vitro precision-medicine lead in a single variant, not established clinical practice, and no clinical trial evidence exists.

Mechanism Target:

Impaired Receptor Trafficking and Surface Expression — Verapamil acts on the trafficking/surface-expression arm of the mechanism rather than on network excitability.

Show evidence (2 references)

PMID:31707987 SUPPORT In Vitro

"However, verapamil treatment for 24 h fully restored the function of R214C mutant receptors, primarily by increasing channel open time."

Reports full in-vitro functional rescue of a specific GABRA1 variant by verapamil, the basis for this investigational approach.

PMID:31707987 SUPPORT In Vitro

"The GABA-evoked currents in R214C GABAA receptors could only be partially restored with benzodiazepine (diazepam) and insulin."

Records the contrasting incomplete rescue by diazepam and insulin, supporting the claim that rescue is mechanism-specific rather than generic.

Adjunctive vinpocetine for loss-of-function variants (investigational)

Action: Pharmacotherapy NCIT:C15986

Agent: vinpocetine CHEBI:32297

Platform: Small molecule

Vinpocetine is a positive allosteric modulator of the GABA-A receptor, so it is mechanistically directed at the loss-of-function arm of the GABRA1 spectrum rather than at network excitability in general. A retrospective observational series of nine patients carrying eight loss-of-function GABA-A receptor variants reported reduced seizure frequency and improvement in non-seizure outcomes on add-on treatment, and a previously published patient with the loss-of-function GABRA1 Arg112Gln variant became seizure-free. This is uncontrolled observational evidence in a small, genotypically mixed cohort treated outside a trial, not established practice, and the same rationale predicts it would be inappropriate for the gain-of-function transmembrane variants at the severe end of this entry's scope.

Mechanism Target:

Loss-of-Function Reduction in GABA-A Receptor Current — Positive allosteric modulation is aimed at restoring current through residual functional receptor, so it addresses the loss-of-function arm specifically and not the gain-of-function arm.

Show evidence (4 references)

PMID:42227896 SUPPORT Human Clinical

"Adjunctive vinpocetine shows promise as a targeted therapy for patients with GABAA receptor LoF variants, decreasing seizure frequency and positively impacting nonseizure factors, with only mild AEs reported."

The study's own summary of its result, supporting vinpocetine as a genotype-directed option in the loss-of-function group.

PMID:42227896 SUPPORT Human Clinical

"Additionally, results of add‐on vinpocetine in a patient with an LoF variant (Arg112Gln) in GABRA1 resulted in seizure freedom and marked improvements in social behavior and cognitive functions."

A GABRA1-specific seizure-freedom outcome. Note this is the paper's account of a previously published patient rather than one of its own nine, which is why the treatment description attributes it that way.

PMID:42227896 SUPPORT Human Clinical

"One improved in adaptive behavior and executive function, whereas the other discontinued vinpocetine due to AEs."

The study's own in-cohort GABRA1 result, and a split one: these are the two patients who shared the GABRA1 p.Gly251Asp variant, and the same variant gave benefit in one and intolerance in the other. This is the strongest reason to treat the approach as investigational rather than established. The quote is trimmed before the variant notation because the validator strips bracketed spans, and p.[Gly251Asp] matches no configured literal_bracket_patterns entry.

+ 1 more reference

Genetic counseling

Action: Genetic Counseling NCIT:C15240

Platform: Behavioral / lifestyle

Because pathogenic GABRA1 variants in the encephalopathic range are typically de novo, recurrence risk for siblings is low but not zero, and counselling should address the possibility of undetected parental gonadal mosaicism. Inherited transmission is documented and is concentrated at the milder end of the spectrum.

Show evidence (1 reference)

PMID:24623842 SUPPORT Human Clinical

"Our results have important implications for diagnostic testing, clinical management, and genetic counseling of patients with this devastating disorder and their families."

The primary report identifying GABRA1 as a cause of severe infantile epileptic encephalopathy explicitly frames genetic counseling as a clinical implication.

🔬

Diagnosis

2

Trio exome/genome sequencing or epilepsy gene panel

Diagnosis is molecular: identification of a heterozygous pathogenic GABRA1 variant on a targeted epilepsy gene panel or on exome/genome sequencing, ideally in a proband-plus-parents (trio) design so that de novo status can be established. This matters because the clinical presentation does not distinguish DEE19 from its differentials — GABRA1 patients are routinely ascertained from within SCN1A-negative Dravet cohorts and from undifferentiated infantile-epilepsy cohorts, so the gene, not the phenotype, is what settles the diagnosis.

Show evidence (3 references)

PMID:24623842 SUPPORT Human Clinical

"We performed whole-exome sequencing in 13 SCN1A-negative patients with Dravet syndrome and targeted resequencing in 67 additional patients to identify new genes for this disorder."

Documents the sequencing-based route by which GABRA1 patients are identified out of a clinically defined, gene-negative epilepsy population.

PMID:24623842 SUPPORT Human Clinical

"Our results have important implications for diagnostic testing, clinical management, and genetic counseling of patients with this devastating disorder and their families."

The primary report frames its findings as directly bearing on diagnostic testing for this population.

PMID:26918889 SUPPORT Human Clinical

"In total, 526 and 145 patients with infantile epilepsy were analyzed by whole-exome sequencing and GABRA1-targeted resequencing, respectively."

Records both diagnostic modalities — untargeted exome sequencing and GABRA1-targeted resequencing — applied to an infantile-epilepsy population.

Functional (electrophysiological) variant classification

Beyond confirming that a variant is present, determining whether it is gain-of-function or loss-of-function is prognostically and therapeutically informative, because the two classes differ in severity and in reported drug response. Classification is done by two-electrode voltage-clamp or patch-clamp electrophysiology of the variant receptor; where functional data are unavailable, the variant's structural location — extracellular domain and small transmembrane loops versus pore-forming transmembrane helices — provides partial prediction. This is a research-grade step rather than a routine clinical assay.

Show evidence (2 references)

PMID:37606373 SUPPORT Human Clinical

"These findings establish the basis for a better understanding of the pathomechanism and a precision medicine approach in GABRA1-related disorders."

Frames functional and structural variant classification as the basis for a precision-medicine approach, which is what this diagnostic step delivers.

PMID:37606373 SUPPORT Human Clinical

"Genetic and electroclinical data of 27 individuals (22 unrelated and 2 families) harboring 20 different GABRA1 variants were collected and accompanied by functional analysis of 19 variants."

Records the functional-analysis workflow applied alongside genetic testing to classify GABRA1 variants.

📊

Prevalence

1

Worldwide

Unknown Ultra Rare

No population-based prevalence or incidence estimate exists for DEE19. The published evidence base consists of gene-panel and exome cohorts and international case series of tens of patients — 16 novel probands in the first phenotypic-spectrum series, 27 individuals in the largest functional cohort, and 5 de novo variants found by screening 671 patients with infantile epilepsy — which delineate the phenotype but cannot support a population rate. The prevalence_class is therefore recorded as the qualitative ULTRA_RARE tier rather than a numeric Orphanet band.

Show evidence (1 reference)

PMID:26918889 SUPPORT Human Clinical

"In total, 526 and 145 patients with infantile epilepsy were analyzed by whole-exome sequencing and GABRA1-targeted resequencing, respectively."

Establishes the denominator of the largest targeted screen (671 patients with infantile epilepsy) that yielded five de novo GABRA1 variants, supporting characterization of DEE19 as a rare cause of infantile epilepsy rather than providing a population rate.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Developmental and Epileptic Encephalopathy 19:

Dravet syndrome (SCN1A)

Overlapping Features Dravet syndrome is the closest clinical differential, and the relationship is not merely a resemblance: GABRA1 variants are found in patients who meet Dravet criteria but are SCN1A-negative. Fever-sensitive seizures beginning in infancy are shared. The distinction is molecular rather than clinical at presentation, which is why gene-panel or exome testing rather than phenotype alone settles it.

Show evidence (1 reference)

PMID:24623842 SUPPORT Human Clinical

"We performed whole-exome sequencing in 13 SCN1A-negative patients with Dravet syndrome and targeted resequencing in 67 additional patients to identify new genes for this disorder."

Establishes that GABRA1 patients are ascertained from within the SCN1A-negative Dravet population, making Dravet syndrome the primary differential.

Juvenile myoclonic epilepsy (GABRA1, milder allelic phenotype)

Overlapping Features Autosomal dominant juvenile myoclonic epilepsy is caused by variants in the same gene and shares myoclonic and tonic-clonic seizures with photosensitivity, but is an idiopathic generalized epilepsy of adolescence with normal development — the opposite end of the GABRA1 severity spectrum from DEE19. It is curated as a separate dismech entry, not as a subtype here.

Show evidence (1 reference)

PMID:27521439 SUPPORT Human Clinical

"The phenotypic spectrum varied from unspecified epilepsy (1), juvenile myoclonic epilepsy (2), photosensitive idiopathic generalized epilepsy (1), and generalized epilepsy with febrile seizures plus (1) to severe epileptic encephalopathies (11)."

Documents that juvenile myoclonic epilepsy and severe epileptic encephalopathy occur within the same GABRA1 allelic series, establishing the milder syndromes as differentials rather than subtypes.

Childhood absence epilepsy (GABRA1 susceptibility)

Overlapping Features Childhood absence epilepsy is another idiopathic generalized epilepsy in which GABRA1 acts as a susceptibility gene alongside CACNA1H, GABRG2 and GABRB3. Absence seizures do occur within the GABRA1 encephalopathy spectrum, so the discriminator is the accompanying developmental impairment and seizure burden rather than the absence seizures themselves.

Show evidence (1 reference)

PMID:26918889 SUPPORT Human Clinical

"GABRA1 mutations have been identified in patients with familial juvenile myoclonic epilepsy, sporadic childhood absence epilepsy, and idiopathic familial generalized epilepsy."

Records childhood absence epilepsy as an established milder GABRA1-associated phenotype distinct from the encephalopathies.

🐁

Animal Models

2

Gabra1 heterozygous knockout mouse

Heterozygous deletion of Gabra1, modeling alpha-1 subunit haploinsufficiency, produces absence seizures and allows the circuit-level consequences of reduced alpha-1 to be measured directly in thalamus.

Species

Mouse

Genotype

Gabra1 heterozygous deletion (Het-KO)

Publication

PMID:25447232

Pathograph links

Impaired GABAergic Inhibitory Neurotransmission recapitulates fidelity: moderate observes: cellular Directly measures the loss of phasic GABAergic inhibition produced by alpha-1 subunit loss in an intact thalamic circuit.

Limitations: Models haploinsufficiency by gene deletion, whereas most human DEE19 variants are missense and may act by dominant-negative or gain-of-function mechanisms rather than simple dosage loss. The mouse phenotype is absence epilepsy, which sits at the milder end of the human spectrum rather than the encephalopathic end this entry curates.

Readouts

Miniature inhibitory postsynaptic current amplitude and frequency in ventrobasal thalamus

Direction: DECREASED

Interpretation: Quantifies the reduction in phasic inhibitory synaptic transmission caused by alpha-1 subunit loss.

Show evidence (1 reference)

PMID:25447232 SUPPORT Model Organism

"In addition, heterozygous α1 subunit deletion substantially reduced miniature inhibitory postsynaptic current (mIPSC) peak amplitudes and frequency in VB."

Reports the direct electrophysiological measurement behind this readout.

Show evidence (1 reference)

PMID:25447232 SUPPORT Model Organism

"We previously demonstrated that heterozygous deletion of Gabra1, the mouse homolog of the human absence epilepsy gene that encodes the GABAA receptor (GABAAR) α1 subunit, causes absence seizures."

Establishes the model as an informative system for the consequences of alpha-1 subunit loss.

Gabra1 A322D knock-in mouse

A knock-in of the human A322D missense variant, which was the first GABRA1 variant linked to epilepsy. The mice develop spontaneous absence seizures and later myoclonic seizures, allowing the cortical network dynamics of two seizure types to be compared in one animal.

Species

Mouse

Genotype

Gabra1+/A322D heterozygous knock-in

Publication

PMID:27573707

Pathograph links

Neuronal Hyperexcitability and Thalamocortical Hypersynchrony partially recapitulates fidelity: moderate observes: tissue Reproduces the network hypersynchrony step, showing increased EEG connectivity at seizure onset with somatosensory cortex leading motor cortex.

Limitations: A322D is a juvenile myoclonic epilepsy allele from the mild end of the GABRA1 spectrum, not a DEE19 encephalopathy allele, and the mouse phenotype is absence and myoclonic seizures rather than an infantile encephalopathy. It therefore models the shared network mechanism but not the severity or developmental impairment that define DEE19.

Readouts

Interelectrode EEG connectivity at seizure onset

Direction: INCREASED

Interpretation: Network synchrony rises at the onset of both absence and myoclonic seizures, the measurable correlate of the hypersynchrony node.

Show evidence (1 reference)

PMID:27573707 SUPPORT Model Organism

"EEG connectivity among all electrode pairs increased at the onset of both SWDs and myoclonic seizures."

Reports the connectivity measurement behind this readout.

Show evidence (1 reference)

PMID:27573707 SUPPORT Model Organism

"Early in life (postnatal day 35, P35), Gabra1+/A322D mice have spontaneous absence seizures with SWDs, and, later in life (P120), they have spontaneous SWDs, myoclonic seizures, and a greater sensitivity to pentylenetetrazol- (PTZ-) evoked myoclonic seizures than wild type mice."

Establishes the model's genotype and spontaneous seizure phenotype, supporting its use as an informative system for GABRA1-driven network hyperexcitability.

{ }

Source YAML

click to show

name: Developmental and Epileptic Encephalopathy 19
creation_date: "2026-09-05T18:58:29Z"
category: Mendelian
description: >-
  A severe early-onset developmental and epileptic encephalopathy (DEE19,
  formerly early infantile epileptic encephalopathy 19 / EIEE19) caused by
  heterozygous, typically de novo, variants in GABRA1, which encodes the
  alpha-1 subunit of the GABA-A receptor — the pentameric ligand-gated chloride
  channel that mediates most fast inhibitory neurotransmission in the mature
  brain. Seizures usually begin in infancy, are frequently multiple in type and
  drug-resistant, and are accompanied by developmental delay, intellectual
  disability, and in the most severe cases developmental regression with
  hypsarrhythmia. The organizing mechanistic fact of this entry is that GABRA1
  is a single gene spanning a wide severity spectrum, and that position within
  the subunit predicts where on that spectrum a patient lands: variants in the
  extracellular domain and small transmembrane loops are loss-of-function and
  produce a milder, often favorable-outcome epilepsy, whereas variants in the
  pore-forming transmembrane helices — whether loss-of-function or
  gain-of-function — produce the severe early-onset encephalopathic phenotype,
  with gain-of-function variants the most severe of all. This entry is scoped to
  that encephalopathic end. The milder GABRA1-associated phenotypes at the other
  end of the same allelic spectrum — autosomal dominant juvenile myoclonic
  epilepsy and childhood absence epilepsy susceptibility, both already curated
  as separate dismech entries — are recorded here as differentials rather than
  as subtypes, because they are established idiopathic generalized epilepsy
  syndromes in their own right and not severity grades of DEE19.
parents:
- Epilepsy
- Channelopathy
disease_term:
  preferred_term: developmental and epileptic encephalopathy, 19
  term:
    id: MONDO:0014328
    label: developmental and epileptic encephalopathy, 19
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0014328
      label: developmental and epileptic encephalopathy, 19
    mapping_predicate: skos:exactMatch
synonyms:
- DEE19
- EIEE19
- early infantile epileptic encephalopathy 19
- epileptic encephalopathy, early infantile, 19
- GABRA1 early infantile epileptic encephalopathy
- GABRA1-related developmental and epileptic encephalopathy
references:
- reference: PMID:37606373
  title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
- reference: PMID:27521439
  title: "Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies."
- reference: PMID:26918889
  title: "De novo GABRA1 mutations in Ohtahara and West syndromes."
- reference: PMID:24623842
  title: "GABRA1 and STXBP1: novel genetic causes of Dravet syndrome."
- reference: PMID:31707987
  title: "Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy."
- reference: PMID:33585817
  title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
- reference: PMID:42227896
  title: "Add-on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss-of-function γ-aminobutyric acid type A receptor variants."
inheritance:
- name: Autosomal dominant (typically de novo)
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    DEE19 is inherited in an autosomal dominant manner, but affected individuals
    in the encephalopathic range almost always carry a de novo heterozygous
    variant rather than an inherited one. Inherited transmission does occur and
    is concentrated at the milder end of the spectrum: in the largest functional
    cohort, the two inherited transmembrane-domain variants were specifically
    noted as the exception to the rule that transmembrane variants cause severe
    phenotypes. ClinGen's Epilepsy Gene Curation Expert Panel classifies the
    GABRA1-epilepsy relationship as Definitive with autosomal dominant
    inheritance.
  evidence:
  - reference: PMID:26918889
    reference_title: "De novo GABRA1 mutations in Ohtahara and West syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified five de novo missense GABRA1 mutations in six unrelated patients.
    explanation: >-
      Documents de novo occurrence of GABRA1 missense variants across six
      unrelated patients with early-onset epileptic encephalopathy, supporting a
      dominant, predominantly de novo mechanism.
  - reference: CGGV:assertion_60478d36-384e-4246-ba8a-730755d6f216-2024-09-03T170000.000Z
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GABRA1 | HGNC:4075 | epilepsy | MONDO:0005027 | AD | Definitive"
    explanation: >-
      ClinGen Epilepsy Gene Curation Expert Panel records the GABRA1-epilepsy
      relationship as Definitive with autosomal dominant inheritance.
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the transmembrane
      domain, we observed 4 missense variants with GoF effect
      and 5 variants with LoF effect, of which 2 were inherited.
    explanation: >-
      Records that inherited transmission occurs but is the exception among
      transmembrane-domain variants, which are otherwise the severe,
      predominantly de novo group.
prevalence:
- population: Worldwide
  measure_type: UNKNOWN
  prevalence_class: ULTRA_RARE
  notes: >-
    No population-based prevalence or incidence estimate exists for DEE19. The
    published evidence base consists of gene-panel and exome cohorts and
    international case series of tens of patients — 16 novel probands in the
    first phenotypic-spectrum series, 27 individuals in the largest functional
    cohort, and 5 de novo variants found by screening 671 patients with
    infantile epilepsy — which delineate the phenotype but cannot support a
    population rate. The prevalence_class is therefore recorded as the
    qualitative ULTRA_RARE tier rather than a numeric Orphanet band.
  evidence:
  - reference: PMID:26918889
    reference_title: "De novo GABRA1 mutations in Ohtahara and West syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In total, 526 and 145 patients with infantile epilepsy were analyzed by whole-exome sequencing and GABRA1-targeted resequencing, respectively.
    explanation: >-
      Establishes the denominator of the largest targeted screen (671 patients
      with infantile epilepsy) that yielded five de novo GABRA1 variants,
      supporting characterization of DEE19 as a rare cause of infantile epilepsy
      rather than providing a population rate.
pathophysiology:
- name: GABRA1 Variant and Alpha-1 Subunit Dysfunction
  description: >-
    The initiating lesion is a heterozygous, typically de novo variant in
    GABRA1, which encodes the alpha-1 subunit of the GABA-A receptor. GABA-A
    receptors are pentameric ligand-gated chloride channels that mediate most
    fast inhibitory neurotransmission in the mature brain; alpha-1 is the most
    abundant alpha subunit in the adult brain, and its expression rises steeply
    over the first postnatal years as it replaces the alpha-2/alpha-3 subunits
    that predominate prenatally. That developmental expression switch is why a
    variant restricted to this subunit produces an epilepsy of infancy and early
    childhood. Most pathogenic variants are missense and cluster either in the
    extracellular domain or in the pore-forming transmembrane helices, and this
    structural position — not merely the presence of a variant — determines
    phenotype severity.
  biological_scale: MOLECULAR
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Ion Channel and Synaptic Dysfunction"
  role: trigger
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Regulation of Membrane Potential
    term:
      id: GO:0042391
      label: regulation of membrane potential
    modifier: ABNORMAL
  - preferred_term: Chemical Synaptic Transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
    modifier: ABNORMAL
  molecular_functions:
  - preferred_term: GABA-gated chloride ion channel activity of the alpha-1-containing receptor
    term:
      id: GO:0022851
      label: GABA-gated chloride ion channel activity
    modifier: ABNORMAL
  evidence:
  - reference: PMID:24623842
    reference_title: "GABRA1 and STXBP1: novel genetic causes of Dravet syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We detected disease-causing mutations in 2 novel genes for Dravet syndrome, with mutations in GABRA1 in 4 cases and STXBP1 in 3.
    explanation: >-
      Establishes GABRA1 variants as a cause of severe infantile-onset epileptic
      encephalopathy, identified by exome sequencing in SCN1A-negative patients.
  - reference: PMID:26918889
    reference_title: "De novo GABRA1 mutations in Ohtahara and West syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our study suggests that de novo GABRA1 mutations can cause early onset epileptic encephalopathies, including Ohtahara syndrome and West syndrome.
    explanation: >-
      Directly attributes early-onset epileptic encephalopathy, including the
      severe electroclinical syndromes of infancy, to de novo GABRA1 variants.
  - reference: PMID:32047208
    reference_title: "A novel de novo variant of GABRA1 causes increased sensitivity for GABA in vitro."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The expression of alpha1 is very low in pre- and perinatal rodent brain, but it increases dramatically after birth in all brain regions
    explanation: >-
      Supports the developmental-expression rationale for why an alpha-1-specific
      lesion manifests as an epilepsy of infancy and early childhood rather than
      prenatally.
  downstream:
  - target: Loss-of-Function Reduction in GABA-A Receptor Current
    causal_link_type: DIRECT
    description: >-
      Variants in the extracellular domain, the small transmembrane loops, and a
      subset of transmembrane-helix positions reduce GABA-gated current.
    evidence:
    - reference: PMID:27521439
      reference_title: "Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Four selected mutations studied functionally revealed a loss of function, without a clear genotype-phenotype correlation.
      explanation: >-
        Functional expression studies of patient variants demonstrate that the
        variant produces loss of receptor function, establishing this causal
        step.
  - target: Gain-of-Function Shift in GABA Sensitivity and Desensitization
    causal_link_type: DIRECT
    description: >-
      A distinct class of variants in the pore-forming transmembrane helices
      increases rather than decreases GABA sensitivity.
    evidence:
    - reference: PMID:37606373
      reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        A more severe phenotype was associated with variants in the pore-forming transmembrane helices. These variants displayed either gain-of-function (GoF) or LoF effects.
      explanation: >-
        Establishes that variants at pore-forming transmembrane positions
        bifurcate functionally into gain-of-function and loss-of-function
        classes, the branch point of this chain.
- name: Loss-of-Function Reduction in GABA-A Receptor Current
  description: >-
    The most frequently demonstrated functional consequence of a pathogenic
    GABRA1 variant is a reduction in GABA-evoked chloride current through
    receptors containing the mutant subunit. Patch-clamp characterization of the
    de novo R214C variant showed the reduction arises from two separable
    defects: a shortened single-channel open time, and a fall in the amount of
    receptor present at all. Loss of function is the effect seen in the
    extracellular-domain variants and in a subset of transmembrane variants.
  biological_scale: MOLECULAR
  role: amplifier
  genetic_context:
    gene:
      preferred_term: GABRA1
      term: {id: hgnc:4075, label: GABRA1}
    allele_type: missense
    variant_origin: DE_NOVO
    zygosity: HETEROZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Missense variants in the extracellular domain and small transmembrane
      loops (for example p.Arg214Cys) are uniformly loss-of-function. Clinically
      they produce a more homogeneous and milder picture — infantile-onset focal
      seizures with fever sensitivity, posterior epileptiform discharges and mild
      cognitive impairment — with a generally favorable outcome. A subset of
      pore-forming transmembrane-helix variants is also loss-of-function but
      clinically more severe.
  molecular_functions:
  - preferred_term: GABA-gated chloride ion channel activity
    term:
      id: GO:0022851
      label: GABA-gated chloride ion channel activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: Chloride Transmembrane Transport
    term:
      id: GO:1902476
      label: chloride transmembrane transport
    modifier: DECREASED
  evidence:
  - reference: PMID:31707987
    reference_title: "Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We found that the GABRA1 (R214C) variant decreased whole-cell GABA-evoked currents by reducing single channel open time and both surface and total GABAA receptor expression levels.
    explanation: >-
      Directly measures reduced GABA-evoked current in a de novo
      encephalopathy-associated variant and identifies the two mechanisms
      producing it.
  - reference: PMID:27521439
    reference_title: "Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Functional analysis of 4 selected mutations was performed using the Xenopus laevis oocyte expression system.
    explanation: >-
      Records the heterologous expression system in which the loss-of-function
      effect of patient GABRA1 variants was established.
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A homogenous phenotype with mild cognitive impairment and infantile onset epilepsy (focal seizures, fever sensitivity, and electroencephalographic posterior epileptiform discharges) was described for variants in the extracellular domain and the small transmembrane loops. These variants displayed loss-of-function (LoF) effects, and the patients generally had a favorable outcome.
    explanation: >-
      Ties extracellular-domain localization to the loss-of-function effect and
      to the milder clinical subgroup, establishing where this node's mechanism
      sits on the severity spectrum.
  - reference: PMID:31707987
    reference_title: "Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We report the identification of a de novo GABRA1 (R214C) variant in a child with epileptic encephalopathy (EE), describe its functional characterization and pathophysiology, and evaluate its potential therapeutic options.
    explanation: >-
      Documents the specific de novo extracellular-domain variant whose
      functional characterization grounds this loss-of-function node.
  downstream:
  - target: Impaired Receptor Trafficking and Surface Expression
    causal_link_type: DIRECT
    description: >-
      Part of the current reduction is not a gating defect at all but a failure
      to deliver and retain receptor at the cell surface.
    evidence:
    - reference: PMID:31707987
      reference_title: "Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Changes to surface and total protein expression levels of WT α1 and R214C α1 were quantified using surface biotinylation assay and western blotting, respectively.
      explanation: >-
        Documents the biotinylation and immunoblot measurement of surface and
        total receptor that establishes the trafficking arm of the mechanism.
  - target: Impaired GABAergic Inhibitory Neurotransmission
    causal_link_type: DIRECT
    description: >-
      Reduced chloride current through synaptic GABA-A receptors weakens fast
      inhibitory synaptic transmission.
    evidence:
    - reference: PMID:31707987
      reference_title: "Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        We conclude that the GABRA1 (R214C) variant reduces channel activity and surface expression of mutant receptors, thereby contributing to the pathogenesis of genetic EE.
      explanation: >-
        Connects the measured reduction in channel activity and surface
        expression to the pathogenesis of genetic epileptic encephalopathy.
- name: Impaired Receptor Trafficking and Surface Expression
  description: >-
    A recurring cellular consequence of GABRA1 variants is that mutant subunits
    fail to reach or be retained at the neuronal surface, so that even
    intrinsically functional receptor is under-represented at the synapse.
    Quantification of the R214C variant showed both surface and total receptor
    protein were reduced, indicating loss of the subunit pool as well as
    mislocalization. This is a distinct mechanism from altered channel gating,
    and it is the arm that pharmacological chaperone strategies target.
  biological_scale: CELLULAR
  role: amplifier
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:31707987
    reference_title: "Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We found that the GABRA1 (R214C) variant decreased whole-cell GABA-evoked currents by reducing single channel open time and both surface and total GABAA receptor expression levels.
    explanation: >-
      Establishes reduced surface and total receptor expression as a measured
      consequence of an encephalopathy-associated GABRA1 variant.
  downstream:
  - target: Impaired GABAergic Inhibitory Neurotransmission
    causal_link_type: DIRECT
    description: >-
      Fewer GABA-A receptors at the synapse means less inhibitory conductance
      available per released quantum of GABA.
- name: Gain-of-Function Shift in GABA Sensitivity and Desensitization
  description: >-
    A functionally opposite class of GABRA1 variants, localized to the
    pore-forming transmembrane helices, increases the apparent potency of GABA
    and alters receptor desensitization without reducing receptor expression or
    trafficking. The de novo A332V variant in transmembrane helix 3 showed
    unchanged protein levels, normal assembly and normal forward trafficking,
    but a significant left shift in apparent GABA potency. Counterintuitively it
    is this gain-of-function group, not the loss-of-function group, that carries
    the most severe early-onset neurodevelopmental phenotype — a pattern also
    seen in the paralogous GABRB3 encephalopathy, and one that matters clinically
    because it inverts the expected direction of GABAergic pharmacotherapy.
  biological_scale: MOLECULAR
  role: amplifier
  genetic_context:
    gene:
      preferred_term: GABRA1
      term: {id: hgnc:4075, label: GABRA1}
    allele_type: missense
    variant_origin: DE_NOVO
    zygosity: HETEROZYGOUS
    functional_impact_category: GAIN_OF_FUNCTION
    description: >-
      Missense variants in the pore-forming transmembrane helices (for example
      p.Ala332Val in TM3) increase apparent GABA potency without reducing
      receptor expression or trafficking. This is the most severe class,
      associated with early infantile developmental and epileptic
      encephalopathy.
  molecular_functions:
  - preferred_term: GABA-gated chloride ion channel activity
    term:
      id: GO:0022851
      label: GABA-gated chloride ion channel activity
    modifier: GAIN_OF_FUNCTION
  evidence:
  - reference: PMID:32047208
    reference_title: "A novel de novo variant of GABRA1 causes increased sensitivity for GABA in vitro."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In vitro assessment revealed unchanged protein levels, regular assembly and forward trafficking to the cell surface. On the functional level a significant left shift of the apparent GABA potency in two-electrode voltage clamp electrophysiology experiments was observed, as well as changes in the extent of desensitization.
    explanation: >-
      Directly measures increased GABA potency and altered desensitization with
      preserved trafficking, defining the gain-of-function mechanism as distinct
      from the loss-of-function/trafficking arm.
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GoF variants were associated with severe early onset neurodevelopmental disorders, including early infantile developmental and epileptic encephalopathy.
    explanation: >-
      Establishes that the gain-of-function class maps onto the severe
      early-onset encephalopathic phenotype this entry curates.
  - reference: PMID:32047208
    reference_title: "A novel de novo variant of GABRA1 causes increased sensitivity for GABA in vitro."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Here we study functional consequences of a novel de novo missense GABRA1 variant, p.(Ala332Val), identified through exome sequencing in an individual affected by early-onset syndromic epileptic encephalopathy. The variant is localised within the transmembrane domain helix 3 (TM3)
    explanation: >-
      Identifies the specific de novo transmembrane-helix missense variant in a
      patient with early-onset epileptic encephalopathy and locates it
      structurally, grounding this gain-of-function node.
  downstream:
  - target: Disrupted Excitation-Inhibition Balance in the Developing Brain
    causal_link_type: DIRECT
    description: >-
      Altered GABA sensitivity and desensitization kinetics disturb the timing
      and magnitude of inhibition during a developmental window in which
      GABAergic signaling also shapes circuit maturation, rather than simply
      increasing useful inhibition.
    evidence:
    - reference: PMID:32047208
      reference_title: "A novel de novo variant of GABRA1 causes increased sensitivity for GABA in vitro."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Thus, the molecular change of function reported here supports pathogenicity and could explain early-onset of seizures in the affected individual.
      explanation: >-
        Links the measured gain-of-function change directly to seizure onset in
        the affected child, supporting this edge rather than only the node.
- name: Impaired GABAergic Inhibitory Neurotransmission
  description: >-
    Loss of alpha-1-containing GABA-A receptor function at the synapse weakens
    fast phasic inhibition. In the heterozygous Gabra1 mouse, this is directly
    measurable as a substantial reduction in the peak amplitude and frequency of
    miniature inhibitory postsynaptic currents in the ventrobasal thalamus, with
    no compensatory increase in tonic GABA-A current — establishing that the
    deficit is specifically in phasic synaptic inhibition. Compensation by other
    alpha subunits is region-specific and incomplete.
  biological_scale: CELLULAR
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
  role: amplifier
  cell_types:
  - preferred_term: GABAergic Neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: GABA Signaling Pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:25447232
    reference_title: "Altered intrathalamic GABAA neurotransmission in a mouse model of a human genetic absence epilepsy syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In addition, heterozygous α1 subunit deletion substantially reduced miniature inhibitory postsynaptic current (mIPSC) peak amplitudes and frequency in VB.
    explanation: >-
      Measures the physiological consequence of alpha-1 loss as a reduction in
      phasic inhibitory synaptic currents in an intact circuit.
  - reference: PMID:25447232
    reference_title: "Altered intrathalamic GABAA neurotransmission in a mouse model of a human genetic absence epilepsy syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      However, there was no change in the expression of the extrasynaptic α4 or δ subunits in VB and, unlike other models of absence epilepsy, no change in tonic GABAAR currents.
    explanation: >-
      Directly reports the absence of any change in tonic GABA-A current,
      establishing that the deficit driving seizures in alpha-1
      haploinsufficiency is in phasic rather than tonic inhibition.
  downstream:
  - target: Disrupted Excitation-Inhibition Balance in the Developing Brain
    causal_link_type: DIRECT
    description: >-
      Weakened inhibition shifts the net balance of excitation and inhibition
      toward excitation.
- name: Disrupted Excitation-Inhibition Balance in the Developing Brain
  description: >-
    Whether inhibition is reduced (loss-of-function variants) or its timing and
    sensitivity are distorted (gain-of-function variants), the shared
    consequence is a shift in the balance of excitation and inhibition in
    maturing cortical and thalamocortical circuits. The developmental timing
    matters: alpha-1 expression rises steeply over the first postnatal years, so
    the imbalance is imposed on circuits that are still being assembled, and
    GABAergic signaling is itself one of the signals shaping that assembly. This
    is why the outcome is an encephalopathy — a disorder of development — rather
    than seizures alone.
  biological_scale: CELLULAR
  role: amplifier
  cell_types:
  - preferred_term: GABAergic Neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: GABA Signaling Pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
    modifier: ABNORMAL
  evidence:
  - reference: PMID:32047208
    reference_title: "A novel de novo variant of GABRA1 causes increased sensitivity for GABA in vitro."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      GABA has multiple functions during neurodevelopment, such as regulating neuronal cell proliferation, maturation and migration
    explanation: >-
      Supports the claim that GABAergic signaling is a developmental signal, so
      that disturbing it during circuit assembly produces a developmental
      disorder and not only seizures.
  downstream:
  - target: Neuronal Hyperexcitability and Thalamocortical Hypersynchrony
    causal_link_type: DIRECT
    description: >-
      Net excitatory bias produces a hyperexcitable, hypersynchronous network
      state.
- name: Neuronal Hyperexcitability and Thalamocortical Hypersynchrony
  description: >-
    The excitation-inhibition shift converts into a hyperexcitable network that
    fires excessively and in synchrony. In the Gabra1 heterozygous mouse the
    ventrobasal thalamus is disinhibited by the loss of phasic GABAergic current,
    while the reticular nucleus paradoxically shows prolonged phasic currents —
    a partial compensation. In the Gabra1 A322D knock-in, EEG connectivity across
    sensorimotor cortex rises at the onset of both absence and myoclonic
    seizures, with somatosensory cortex leading motor cortex, showing that
    distinct seizure types in the same animal recruit overlapping cortical
    networks.
  biological_scale: TISSUE
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  role: central_effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Action Potential
    term:
      id: GO:0001508
      label: action potential
    modifier: INCREASED
  evidence:
  - reference: PMID:25447232
    reference_title: "Altered intrathalamic GABAA neurotransmission in a mouse model of a human genetic absence epilepsy syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In addition, heterozygous loss of α1 subunit disinhibits VB by substantially reducing phasic GABAergic currents and surprisingly, it also increases nRT inhibition by prolonging phasic currents.
    explanation: >-
      Localizes the disinhibition produced by alpha-1 loss to a specific
      thalamic node of the seizure-generating network.
  - reference: PMID:27573707
    reference_title: "Dynamics of sensorimotor cortex activation during absence and myoclonic seizures in a mouse model of juvenile myoclonic epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      EEG connectivity among all electrode pairs increased at the onset of both SWDs and myoclonic seizures.
    explanation: >-
      Measures the rise in network synchrony at seizure onset in a Gabra1
      knock-in mouse, supporting hypersynchrony as the central effector step.
  downstream:
  - target: Seizure Generation in the Developing Brain
    causal_link_type: DIRECT
    description: >-
      Hypersynchronous network discharges manifest clinically as seizures.
- name: Seizure Generation in the Developing Brain
  description: >-
    Hypersynchronous discharges manifest as recurrent seizures, typically
    beginning in the first year of life. The seizure repertoire is broad rather
    than syndrome-specific: focal and generalized tonic-clonic seizures, typical
    and atypical absences, myoclonic and atonic seizures, and epileptic spasms
    are all reported, and individual patients commonly have several types. In the
    most severe presentations the electroclinical picture is that of a recognized
    encephalopathy of infancy — West syndrome with hypsarrhythmia, or Ohtahara
    syndrome.
  biological_scale: ORGANISM
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Seizure Generation and Epileptogenesis"
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizure types included focal and
      generalized tonic–clonic seizures, typical and atypical absences,
      myoclonic and atonic seizures, and epileptic spasms.
    explanation: >-
      Enumerates the seizure repertoire produced by GABRA1 variants in a
      27-individual cohort, supporting the breadth of this effector step.
  - reference: PMID:26918889
    reference_title: "De novo GABRA1 mutations in Ohtahara and West syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      p.P260L, p.M263T, and p.M263I in transmembrane spanning domain 1 (TM1) were identified in three unrelated patients with West syndrome and a patient with Ohtahara syndrome, respectively
    explanation: >-
      Anchors the most severe electroclinical syndromes of infancy to specific
      de novo transmembrane-domain GABRA1 variants.
  downstream:
  - target: Drug-Resistant Epilepsy with Developmental Impairment
    causal_link_type: DIRECT
    description: >-
      Ongoing seizures and the underlying inhibitory deficit together produce the
      chronic encephalopathic outcome.
  - target: Infantile-onset epilepsy
    causal_link_type: DIRECT
    description: >-
      Seizure generation in the first year of life is what presents clinically as
      infantile-onset epilepsy.
  - target: Bilateral tonic-clonic seizure
    causal_link_type: DIRECT
    description: >-
      Generalized hypersynchronous discharge manifests as the tonic-clonic
      seizure type, the most common in the GABRA1 cohort.
  - target: Myoclonic seizure
    causal_link_type: DIRECT
    description: >-
      Brief generalized discharges manifest as myoclonic seizures.
  - target: Epileptic spasm
    causal_link_type: DIRECT
    description: >-
      In the severe transmembrane-variant group, seizure generation in the
      immature brain takes the form of epileptic spasms.
  - target: Fever-sensitive seizures
    causal_link_type: DIRECT
    description: >-
      Fever lowers the threshold for seizure generation, producing the
      fever-precipitated seizures prominent in the loss-of-function group.
  - target: EEG with photoparoxysmal response
    causal_link_type: DIRECT
    description: >-
      The hyperexcitable network responds pathologically to photic stimulation,
      recorded as a photoparoxysmal EEG response.
  - target: Hypsarrhythmia
    causal_link_type: DIRECT
    description: >-
      The severely disorganized interictal state of the epileptic infant brain is
      recorded as hypsarrhythmia.
- name: Drug-Resistant Epilepsy with Developmental Impairment
  description: >-
    The clinical endpoint is chronic epilepsy accompanied by developmental delay
    or intellectual disability, which affects the large majority of individuals
    with a pathogenic GABRA1 variant. Outcome tracks the functional class of the
    variant: extracellular-domain loss-of-function variants generally have a
    favorable outcome, with most patients becoming seizure-free on monotherapy
    after an initial stormy phase, whereas transmembrane-helix variants —
    particularly gain-of-function ones — produce refractory seizures, regression
    and severe impairment. Additional neurodevelopmental and movement problems
    (autism spectrum disorder, ADHD and behavioral disturbance, ataxia, tremor,
    dystonia) are common.
  biological_scale: ORGANISM
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  role: consequence
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most
      individuals (21/24, 88%) had various degrees of ID or
      developmental delay.
    explanation: >-
      Quantifies the developmental component of the encephalopathy across the
      cohort, establishing this consequence node.
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Generally, variants in the transmembrane helices cause more severe phenotypes, in particular GoF variants.
    explanation: >-
      Supports the claim that outcome severity tracks the structural position and
      functional class of the variant.
  downstream:
  - target: Global developmental delay and intellectual disability
    causal_link_type: DIRECT
    description: >-
      The developmental arm of the encephalopathy presents as delay or
      intellectual disability, affecting 88% of the cohort.
  - target: Developmental regression
    causal_link_type: DIRECT
    description: >-
      In the most severely affected patients the developmental course is not
      merely delayed but regressive, with loss of acquired skills.
  - target: Autism spectrum disorder
    causal_link_type: DIRECT
    description: >-
      Autism spectrum disorder is part of the broader neurodevelopmental burden
      accompanying the encephalopathy.
  - target: Behavioral disturbance and ADHD
    causal_link_type: DIRECT
    description: >-
      Behavioral disturbance and attention-deficit/hyperactivity disorder are a
      common non-cognitive neurodevelopmental accompaniment, reported at the same
      rate as the movement-disorder group in the source cohort.
  - target: Ataxia and movement disorder
    causal_link_type: DIRECT
    description: >-
      Movement disorders accompany the encephalopathy in about a third of
      individuals.
phenotypes:
- category: Neurological
  name: Infantile-onset epilepsy
  description: >-
    Epilepsy affecting nearly all individuals with a pathogenic GABRA1 variant,
    with onset typically in the first year of life. In the severe
    encephalopathic group, onset ranges from the first day of life to 15 months
    with a mean of 7 months.
  phenotype_term:
    preferred_term: Infantile-onset seizures
    term:
      id: HP:0001250
      label: Seizure
    onset:
      onset_category: INFANTILE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:27521439
    reference_title: "Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the epileptic encephalopathy group, the patients had seizures beginning between the first day of life and 15 months, with a mean of 7 months.
    explanation: >-
      Directly reports the age-at-onset distribution in the encephalopathic
      subgroup this entry curates.
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Epilepsy was diagnosed in 23 of 24 (96%) subjects,
    explanation: >-
      Quantifies epilepsy frequency across the GABRA1 cohort, supporting the
      VERY_FREQUENT band.
- category: Neurological
  name: Bilateral tonic-clonic seizure
  description: >-
    Tonic-clonic seizures are the single most common seizure type across the
    GABRA1 spectrum, reported in 56% of patients in the first phenotypic-spectrum
    series and shared between the mild and severe ends.
  phenotype_term:
    preferred_term: Bilateral tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  frequency: FREQUENT
  evidence:
  - reference: PMID:27521439
    reference_title: "Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Predominant seizure types in all patients were tonic-clonic in 9 participants (56%) and myoclonic seizures in 5 (31%).
    explanation: >-
      Quantifies tonic-clonic seizures as the predominant seizure type in the
      GABRA1 cohort.
- category: Neurological
  name: Myoclonic seizure
  description: >-
    Myoclonic seizures occur in roughly a third of patients and, together with
    tonic-clonic seizures and photosensitivity, form the recurring seizure
    signature shared across mild and severe GABRA1 phenotypes.
  phenotype_term:
    preferred_term: Myoclonic seizure
    term:
      id: HP:0032794
      label: Myoclonic seizure
  frequency: FREQUENT
  evidence:
  - reference: PMID:27521439
    reference_title: "Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Myoclonic and tonic-clonic seizures with pathologic response to photic stimulation are common and shared features in both mild and severe phenotypes.
    explanation: >-
      Identifies myoclonic seizures as a common and cross-spectrum feature of
      GABRA1-related epilepsy.
- category: Neurological
  name: Epileptic spasm
  description: >-
    Epileptic spasms occur in the severe end of the spectrum and, when
    accompanied by hypsarrhythmia and developmental regression, constitute West
    syndrome. De novo GABRA1 transmembrane-domain variants have been identified
    in patients with West syndrome and with Ohtahara syndrome.
  phenotype_term:
    preferred_term: Epileptic spasm
    term:
      id: HP:0011097
      label: Epileptic spasm
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:26918889
    reference_title: "De novo GABRA1 mutations in Ohtahara and West syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      p.P260L, p.M263T, and p.M263I in transmembrane spanning domain 1 (TM1) were identified in three unrelated patients with West syndrome and a patient with Ohtahara syndrome, respectively
    explanation: >-
      Documents West syndrome, whose defining seizure type is epileptic spasms,
      in patients with de novo GABRA1 variants.
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presented with
      infantile spasms, developmental regression, and
      hypsarrhythmia at the age of 5 months.
    explanation: >-
      A specific patient with a transmembrane-domain variant presenting with the
      full West syndrome triad.
- category: Neurological
  name: Global developmental delay and intellectual disability
  description: >-
    Developmental delay or intellectual disability of varying degree affects the
    large majority of individuals, and its presence alongside epilepsy is what
    makes this a developmental and epileptic encephalopathy rather than an
    epilepsy alone.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most
      individuals (21/24, 88%) had various degrees of ID or
      developmental delay.
    explanation: >-
      Quantifies developmental delay/intellectual disability at 88% of the
      cohort, supporting the VERY_FREQUENT band.
- category: Neurological
  name: Developmental regression
  description: >-
    Loss of previously acquired skills, characteristically accompanying the onset
    of infantile spasms and hypsarrhythmia in the most severely affected
    patients.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presented with
      infantile spasms, developmental regression, and
      hypsarrhythmia at the age of 5 months.
    explanation: >-
      Documents developmental regression as part of the severe
      transmembrane-variant presentation.
- category: Neurological
  name: Hypsarrhythmia
  description: >-
    The chaotic, high-amplitude interictal EEG pattern of West syndrome, reported
    in severely affected GABRA1 patients presenting with infantile spasms.
  phenotype_term:
    preferred_term: Hypsarrhythmia
    term:
      id: HP:0002521
      label: Hypsarrhythmia
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presented with
      infantile spasms, developmental regression, and
      hypsarrhythmia at the age of 5 months.
    explanation: >-
      Directly documents hypsarrhythmia in a patient with a de novo GABRA1
      transmembrane-domain variant.
- category: Neurological
  name: EEG with photoparoxysmal response
  description: >-
    A pathological EEG response to photic stimulation, present in over a third of
    GABRA1 patients and one of the features that recurs across both the mild and
    the severe ends of the spectrum.
  phenotype_term:
    preferred_term: EEG with photoparoxysmal response
    term:
      id: HP:0010852
      label: EEG with photoparoxysmal response
  frequency: FREQUENT
  evidence:
  - reference: PMID:27521439
    reference_title: "Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      EEG showed a generalized photoparoxysmal response in 6 patients (37%).
    explanation: >-
      Directly quantifies the photoparoxysmal EEG response in the GABRA1 cohort.
- category: Neurological
  name: Fever-sensitive seizures
  description: >-
    Seizures precipitated or worsened by fever, prominent in the
    extracellular-domain loss-of-function group where focal hemiclonic seizures
    were elicited by high fever. This overlaps clinically with Dravet syndrome,
    and GABRA1 variants are indeed found in SCN1A-negative patients meeting
    Dravet criteria.
  phenotype_term:
    preferred_term: Fever-sensitive seizures
    term:
      id: HP:0002373
      label: Febrile seizure (within the age range of 3 months to 6 years)
  frequency: FREQUENT
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fever sensitivity was reported in 9 of 10 (90%)
    explanation: >-
      Quantifies fever sensitivity in the extracellular-domain subgroup. The 90%
      is that subgroup's rate, not the cohort's. Summing the Table 2 row across
      all variant classes (9/10, 1/3, 0/2, 3/4, 0/2) gives 13 of the 21
      individuals with fever data, about 62%, which is the band recorded here.
- category: Neurological
  name: Autism spectrum disorder
  description: >-
    Autism spectrum disorder occurs in a minority of individuals, part of the
    broader neurodevelopmental burden accompanying the epilepsy.
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      autism spectrum disorder (ASD; 5/24,
      21%)
    explanation: >-
      Records autism spectrum disorder in 5 of 24 individuals (21%) in the
      GABRA1 cohort.
- category: Neurological
  name: Behavioral disturbance and ADHD
  description: >-
    Behavioral disturbance or attention-deficit/hyperactivity disorder affects
    just under a third of individuals, more common in this cohort than autism
    spectrum disorder (21%). It is not the single most frequent accompaniment
    after developmental delay: the source reports movement disorders at the
    identical 7/24 (29%), so the two are tied rather than ranked.
  phenotype_term:
    preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      and behavioral disturbances or attention-de ﬁcit/
      hyperactivity disorder (ADHD; 7/24, 29%).
    explanation: >-
      Quantifies behavioral disturbance and ADHD at 7 of 24 individuals (29%) in
      the GABRA1 cohort. The quoted text preserves the ligature and spacing
      artifacts present in the cached source.
- category: Neurological
  name: Ataxia and movement disorder
  description: >-
    Movement disorders including ataxia, poor coordination, tremor, dystonia and
    cerebral palsy were reported in about a third of individuals.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      including ataxia, poor coor dination, tremor, dystonia,
      and cerebral palsy, were also reported (7/24, 29%).
    explanation: >-
      Quantifies the movement-disorder burden in the GABRA1 cohort. The quoted
      text preserves the spacing artifact present in the cached source.
genetic:
- name: GABRA1
  gene_term:
    preferred_term: GABRA1
    term:
      id: hgnc:4075
      label: GABRA1
  association: >-
    GABRA1 (5q34) encodes the alpha-1 subunit of the GABA-A receptor.
    Heterozygous, typically de novo, predominantly missense variants cause
    developmental and epileptic encephalopathy 19. The variant landscape is
    organized by structural position within the subunit: extracellular-domain and
    small-transmembrane-loop variants are loss-of-function and produce a milder
    epilepsy with generally favorable outcome, whereas pore-forming
    transmembrane-helix variants — which may be either loss-of-function or
    gain-of-function — produce the severe encephalopathic phenotype, the
    gain-of-function subset being the most severe. ClinGen classifies the
    GABRA1-epilepsy relationship as Definitive.
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  inheritance:
  - name: Autosomal dominant (typically de novo)
    evidence:
    - reference: PMID:26918889
      reference_title: "De novo GABRA1 mutations in Ohtahara and West syndromes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We identified five de novo missense GABRA1 mutations in six unrelated patients.
      explanation: >-
        Supports the dominant, predominantly de novo mode of inheritance for
        encephalopathy-causing GABRA1 variants.
  evidence:
  - reference: CGGV:assertion_60478d36-384e-4246-ba8a-730755d6f216-2024-09-03T170000.000Z
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GABRA1 | HGNC:4075 | epilepsy | MONDO:0005027 | AD | Definitive"
    explanation: >-
      ClinGen Epilepsy Gene Curation Expert Panel classifies the GABRA1-epilepsy
      gene-disease relationship as Definitive.
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic and electroclinical data of 27 individuals (22 unrelated and 2 families) harboring 20 different GABRA1 variants were collected and accompanied by functional analysis of 19 variants.
    explanation: >-
      Establishes the size and design of the cohort underpinning the
      structure-function organization of the GABRA1 variant landscape.
  - reference: PMID:24623842
    reference_title: "GABRA1 and STXBP1: novel genetic causes of Dravet syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We show that GABRA1 and STXBP1 make a significant contribution to Dravet syndrome after SCN1A abnormalities have been excluded.
    explanation: >-
      Quantifies GABRA1's contribution to severe infantile epileptic
      encephalopathy in the SCN1A-negative population.
treatments:
- name: Broad-spectrum antiseizure pharmacotherapy
  description: >-
    Antiseizure medication is the mainstay of management. Response is strongly
    stratified by variant class: in the extracellular-domain loss-of-function
    group, most patients become seizure-free on monotherapy after an initial
    stormy phase, whereas antiseizure medications are reported to be ineffective
    in patients with gain-of-function variants and severe epilepsy. Within the
    loss-of-function group the choice of agent appears to be gene-specific,
    with levetiracetam identified as the most effective drug for GABRA1
    (as against valproate for the paralogous GABRB3). This is a cohort
    observation rather than a trial result, so it is a treatment lead and not an
    established first-line recommendation.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: valproic acid
      term:
        id: CHEBI:39867
        label: valproic acid
    - preferred_term: levetiracetam
      term:
        id: CHEBI:6437
        label: levetiracetam
  target_mechanisms:
  - target: Neuronal Hyperexcitability and Thalamocortical Hypersynchrony
    description: >-
      Antiseizure medications act on the hyperexcitable, hypersynchronous network
      state rather than on the receptor lesion itself.
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      6 of 11 (55%) subjects became seizure-free on
      monotherapy at an age ranging from 9 months to 6 years,
    explanation: >-
      Reports the favorable monotherapy response in the milder
      extracellular-domain subgroup, establishing that variant class predicts
      treatment response.
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Conversely, ASMs are ineffective in patients
      with GoF GABRA1 variants with severe epilepsy, and this
      was also observed for individuals harboring pathogenic
      GABRB3 variants located in the transmembrane
      domain.
    explanation: >-
      Refutes any claim that broad-spectrum antiseizure pharmacotherapy is
      reliably effective across DEE19, by stating directly that antiseizure
      medications are ineffective in the gain-of-function group with severe
      epilepsy — the group this entry is scoped to.
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Interestingly the most effective treatment
      for LoF variants in GABRA1 and GABRB3 varies, with
      LEV identi ﬁed for GABRA1 individuals versus VPA in
      GABRB3.
    explanation: >-
      Identifies levetiracetam as the most effective agent in the
      loss-of-function group specifically for GABRA1, distinguishing it from the
      paralogous GABRB3 where valproate is preferred. The quoted text preserves
      the ligature artifact present in the cached source.
- name: Corticotropin and corticosteroid therapy for infantile spasms
  description: >-
    Where the presentation is West syndrome with infantile spasms, the standard
    spasm-directed treatments apply. A GABRA1 transmembrane-variant patient whose
    spasms had failed conventional antiseizure medication responded to
    adrenocorticotropic hormone and prednisolone and achieved seizure freedom,
    although EEG abnormalities persisted.
  notes: >-
    therapeutic_modality is single-valued and is set from adrenocorticotropic
    hormone, which is a peptide; the prednisolone arm of the same treatment is a
    small molecule. The tag describes the corticotropin component, not the whole
    treatment.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: corticotropin
      term:
        id: CHEBI:3892
        label: corticotropin
    - preferred_term: prednisolone
      term:
        id: CHEBI:8378
        label: prednisolone
  target_mechanisms:
  - target: Seizure Generation in the Developing Brain
    description: >-
      Hormonal therapy suppresses the epileptic spasms phenotype rather than
      correcting the receptor defect.
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Infantile spasms
      were responsive to adrenocorticotropic hormone
    explanation: >-
      Documents response of GABRA1-associated infantile spasms to
      adrenocorticotropic hormone in a specific patient. The sentence continues
      "and prednisolone" in the source, but that word is split across a
      line-break hyphen in the cached PDF extraction and so cannot be quoted
      without corrupting it; prednisolone is therefore carried in the
      description and therapeutic_agent rather than in this quote.
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      and the patient achieved seizure freedom, despite
      the persistence of almost continuous EEG abnormalities,
    explanation: >-
      Records the outcome of that hormonal therapy — clinical seizure freedom
      despite persisting EEG abnormality — which is why this treatment is
      described as suppressing the spasms phenotype rather than correcting the
      receptor defect.
- name: Variant-specific pharmacological rescue (investigational)
  description: >-
    Because different GABRA1 variants disable the receptor by different
    mechanisms, agents that address the specific defect are being explored. For
    the trafficking-deficient R214C variant, 24-hour verapamil treatment fully
    restored mutant receptor function in vitro, primarily by increasing channel
    open time, whereas diazepam and insulin produced only partial restoration.
    This is an in-vitro precision-medicine lead in a single variant, not
    established clinical practice, and no clinical trial evidence exists.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: verapamil
      term:
        id: CHEBI:9948
        label: verapamil
  target_mechanisms:
  - target: Impaired Receptor Trafficking and Surface Expression
    description: >-
      Verapamil acts on the trafficking/surface-expression arm of the mechanism
      rather than on network excitability.
  evidence:
  - reference: PMID:31707987
    reference_title: "Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      However, verapamil treatment for 24 h fully restored the function of R214C mutant receptors, primarily by increasing channel open time.
    explanation: >-
      Reports full in-vitro functional rescue of a specific GABRA1 variant by
      verapamil, the basis for this investigational approach.
  - reference: PMID:31707987
    reference_title: "Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The GABA-evoked currents in R214C GABAA receptors could only be partially restored with benzodiazepine (diazepam) and insulin.
    explanation: >-
      Records the contrasting incomplete rescue by diazepam and insulin,
      supporting the claim that rescue is mechanism-specific rather than generic.
- name: Adjunctive vinpocetine for loss-of-function variants (investigational)
  description: >-
    Vinpocetine is a positive allosteric modulator of the GABA-A receptor, so it
    is mechanistically directed at the loss-of-function arm of the GABRA1
    spectrum rather than at network excitability in general. A retrospective
    observational series of nine patients carrying eight loss-of-function GABA-A
    receptor variants reported reduced seizure frequency and improvement in
    non-seizure outcomes on add-on treatment, and a previously published patient
    with the loss-of-function GABRA1 Arg112Gln variant became seizure-free. This
    is uncontrolled observational evidence in a small, genotypically mixed
    cohort treated outside a trial, not established practice, and the same
    rationale predicts it would be inappropriate for the gain-of-function
    transmembrane variants at the severe end of this entry's scope.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: vinpocetine
      term:
        id: CHEBI:32297
        label: Vinpocetine
  target_mechanisms:
  - target: Loss-of-Function Reduction in GABA-A Receptor Current
    description: >-
      Positive allosteric modulation is aimed at restoring current through
      residual functional receptor, so it addresses the loss-of-function arm
      specifically and not the gain-of-function arm.
  evidence:
  - reference: PMID:42227896
    reference_title: "Add-on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss-of-function γ-aminobutyric acid type A receptor variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Adjunctive vinpocetine shows promise as a targeted therapy for patients with GABAA receptor LoF variants, decreasing seizure frequency and positively impacting nonseizure factors, with only mild AEs reported.
    explanation: >-
      The study's own summary of its result, supporting vinpocetine as a
      genotype-directed option in the loss-of-function group.
  - reference: PMID:42227896
    reference_title: "Add-on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss-of-function γ-aminobutyric acid type A receptor variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, results of add‐on vinpocetine in a patient with an LoF variant (Arg112Gln) in GABRA1 resulted in seizure freedom and marked improvements in social behavior and cognitive functions.
    explanation: >-
      A GABRA1-specific seizure-freedom outcome. Note this is the paper's
      account of a previously published patient rather than one of its own nine,
      which is why the treatment description attributes it that way.
  - reference: PMID:42227896
    reference_title: "Add-on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss-of-function γ-aminobutyric acid type A receptor variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One improved in adaptive behavior and executive function, whereas the other discontinued vinpocetine due to AEs.
    explanation: >-
      The study's own in-cohort GABRA1 result, and a split one: these are the two
      patients who shared the GABRA1 p.Gly251Asp variant, and the same variant
      gave benefit in one and intolerance in the other. This is the strongest
      reason to treat the approach as investigational rather than established.
      The quote is trimmed before the variant notation because the validator
      strips bracketed spans, and p.[Gly251Asp] matches no configured
      literal_bracket_patterns entry.
  - reference: PMID:42227896
    reference_title: "Add-on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss-of-function γ-aminobutyric acid type A receptor variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nine patients harboring eight GABAA receptor LoF variants were given add-on vinpocetine treatment.
    explanation: >-
      Records the cohort size and genotypic heterogeneity, which is why this is
      described as investigational rather than established.
- name: Genetic counseling
  description: >-
    Because pathogenic GABRA1 variants in the encephalopathic range are typically
    de novo, recurrence risk for siblings is low but not zero, and counselling
    should address the possibility of undetected parental gonadal mosaicism.
    Inherited transmission is documented and is concentrated at the milder end of
    the spectrum.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:24623842
    reference_title: "GABRA1 and STXBP1: novel genetic causes of Dravet syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our results have important implications for diagnostic testing, clinical management, and genetic counseling of patients with this devastating disorder and their families.
    explanation: >-
      The primary report identifying GABRA1 as a cause of severe infantile
      epileptic encephalopathy explicitly frames genetic counseling as a clinical
      implication.
animal_models:
- name: Gabra1 heterozygous knockout mouse
  species: Mouse
  genotype: Gabra1 heterozygous deletion (Het-KO)
  publication: PMID:25447232
  description: >-
    Heterozygous deletion of Gabra1, modeling alpha-1 subunit
    haploinsufficiency, produces absence seizures and allows the circuit-level
    consequences of reduced alpha-1 to be measured directly in thalamus.
  modeled_mechanisms:
  - target: Impaired GABAergic Inhibitory Neurotransmission
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Directly measures the loss of phasic GABAergic inhibition produced by
      alpha-1 subunit loss in an intact thalamic circuit.
    limitations: >-
      Models haploinsufficiency by gene deletion, whereas most human DEE19
      variants are missense and may act by dominant-negative or gain-of-function
      mechanisms rather than simple dosage loss. The mouse phenotype is absence
      epilepsy, which sits at the milder end of the human spectrum rather than
      the encephalopathic end this entry curates.
    readouts:
    - name: Miniature inhibitory postsynaptic current amplitude and frequency in ventrobasal thalamus
      target: Impaired GABAergic Inhibitory Neurotransmission
      direction: DECREASED
      interpretation: >-
        Quantifies the reduction in phasic inhibitory synaptic transmission
        caused by alpha-1 subunit loss.
      evidence:
      - reference: PMID:25447232
        reference_title: "Altered intrathalamic GABAA neurotransmission in a mouse model of a human genetic absence epilepsy syndrome."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          In addition, heterozygous α1 subunit deletion substantially reduced miniature inhibitory postsynaptic current (mIPSC) peak amplitudes and frequency in VB.
        explanation: >-
          Reports the direct electrophysiological measurement behind this
          readout.
    evidence:
    - reference: PMID:25447232
      reference_title: "Altered intrathalamic GABAA neurotransmission in a mouse model of a human genetic absence epilepsy syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We previously demonstrated that heterozygous deletion of Gabra1, the mouse homolog of the human absence epilepsy gene that encodes the GABAA receptor (GABAAR) α1 subunit, causes absence seizures.
      explanation: >-
        Establishes the model as an informative system for the consequences of
        alpha-1 subunit loss.
- name: Gabra1 A322D knock-in mouse
  species: Mouse
  genotype: Gabra1+/A322D heterozygous knock-in
  publication: PMID:27573707
  description: >-
    A knock-in of the human A322D missense variant, which was the first GABRA1
    variant linked to epilepsy. The mice develop spontaneous absence seizures and
    later myoclonic seizures, allowing the cortical network dynamics of two
    seizure types to be compared in one animal.
  modeled_mechanisms:
  - target: Neuronal Hyperexcitability and Thalamocortical Hypersynchrony
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    description: >-
      Reproduces the network hypersynchrony step, showing increased EEG
      connectivity at seizure onset with somatosensory cortex leading motor
      cortex.
    limitations: >-
      A322D is a juvenile myoclonic epilepsy allele from the mild end of the
      GABRA1 spectrum, not a DEE19 encephalopathy allele, and the mouse
      phenotype is absence and myoclonic seizures rather than an infantile
      encephalopathy. It therefore models the shared network mechanism but not
      the severity or developmental impairment that define DEE19.
    readouts:
    - name: Interelectrode EEG connectivity at seizure onset
      target: Neuronal Hyperexcitability and Thalamocortical Hypersynchrony
      direction: INCREASED
      interpretation: >-
        Network synchrony rises at the onset of both absence and myoclonic
        seizures, the measurable correlate of the hypersynchrony node.
      evidence:
      - reference: PMID:27573707
        reference_title: "Dynamics of sensorimotor cortex activation during absence and myoclonic seizures in a mouse model of juvenile myoclonic epilepsy."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          EEG connectivity among all electrode pairs increased at the onset of both SWDs and myoclonic seizures.
        explanation: >-
          Reports the connectivity measurement behind this readout.
    evidence:
    - reference: PMID:27573707
      reference_title: "Dynamics of sensorimotor cortex activation during absence and myoclonic seizures in a mouse model of juvenile myoclonic epilepsy."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Early in life (postnatal day 35, P35), Gabra1+/A322D mice have spontaneous absence seizures with SWDs, and, later in life (P120), they have spontaneous SWDs, myoclonic seizures, and a greater sensitivity to pentylenetetrazol- (PTZ-) evoked myoclonic seizures than wild type mice.
      explanation: >-
        Establishes the model's genotype and spontaneous seizure phenotype,
        supporting its use as an informative system for GABRA1-driven network
        hyperexcitability.
diagnosis:
- name: Trio exome/genome sequencing or epilepsy gene panel
  description: >-
    Diagnosis is molecular: identification of a heterozygous pathogenic GABRA1
    variant on a targeted epilepsy gene panel or on exome/genome sequencing,
    ideally in a proband-plus-parents (trio) design so that de novo status can be
    established. This matters because the clinical presentation does not
    distinguish DEE19 from its differentials — GABRA1 patients are routinely
    ascertained from within SCN1A-negative Dravet cohorts and from undifferentiated
    infantile-epilepsy cohorts, so the gene, not the phenotype, is what settles
    the diagnosis.
  evidence:
  - reference: PMID:24623842
    reference_title: "GABRA1 and STXBP1: novel genetic causes of Dravet syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We performed whole-exome sequencing in 13 SCN1A-negative patients with Dravet syndrome and targeted resequencing in 67 additional patients to identify new genes for this disorder.
    explanation: >-
      Documents the sequencing-based route by which GABRA1 patients are
      identified out of a clinically defined, gene-negative epilepsy population.
  - reference: PMID:24623842
    reference_title: "GABRA1 and STXBP1: novel genetic causes of Dravet syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our results have important implications for diagnostic testing, clinical management, and genetic counseling of patients with this devastating disorder and their families.
    explanation: >-
      The primary report frames its findings as directly bearing on diagnostic
      testing for this population.
  - reference: PMID:26918889
    reference_title: "De novo GABRA1 mutations in Ohtahara and West syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In total, 526 and 145 patients with infantile epilepsy were analyzed by whole-exome sequencing and GABRA1-targeted resequencing, respectively.
    explanation: >-
      Records both diagnostic modalities — untargeted exome sequencing and
      GABRA1-targeted resequencing — applied to an infantile-epilepsy population.
- name: Functional (electrophysiological) variant classification
  description: >-
    Beyond confirming that a variant is present, determining whether it is
    gain-of-function or loss-of-function is prognostically and therapeutically
    informative, because the two classes differ in severity and in reported drug
    response. Classification is done by two-electrode voltage-clamp or
    patch-clamp electrophysiology of the variant receptor; where functional data
    are unavailable, the variant's structural location — extracellular domain and
    small transmembrane loops versus pore-forming transmembrane helices —
    provides partial prediction. This is a research-grade step rather than a
    routine clinical assay.
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings establish the basis for a better understanding of the pathomechanism and a precision medicine approach in GABRA1-related disorders.
    explanation: >-
      Frames functional and structural variant classification as the basis for a
      precision-medicine approach, which is what this diagnostic step delivers.
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic and electroclinical data of 27 individuals (22 unrelated and 2 families) harboring 20 different GABRA1 variants were collected and accompanied by functional analysis of 19 variants.
    explanation: >-
      Records the functional-analysis workflow applied alongside genetic testing
      to classify GABRA1 variants.
differential_diagnoses:
- name: Dravet syndrome (SCN1A)
  description: >-
    Dravet syndrome is the closest clinical differential, and the relationship is
    not merely a resemblance: GABRA1 variants are found in patients who meet
    Dravet criteria but are SCN1A-negative. Fever-sensitive seizures beginning in
    infancy are shared. The distinction is molecular rather than clinical at
    presentation, which is why gene-panel or exome testing rather than
    phenotype alone settles it.
  evidence:
  - reference: PMID:24623842
    reference_title: "GABRA1 and STXBP1: novel genetic causes of Dravet syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We performed whole-exome sequencing in 13 SCN1A-negative patients with Dravet syndrome and targeted resequencing in 67 additional patients to identify new genes for this disorder.
    explanation: >-
      Establishes that GABRA1 patients are ascertained from within the
      SCN1A-negative Dravet population, making Dravet syndrome the primary
      differential.
- name: Juvenile myoclonic epilepsy (GABRA1, milder allelic phenotype)
  description: >-
    Autosomal dominant juvenile myoclonic epilepsy is caused by variants in the
    same gene and shares myoclonic and tonic-clonic seizures with
    photosensitivity, but is an idiopathic generalized epilepsy of adolescence
    with normal development — the opposite end of the GABRA1 severity spectrum
    from DEE19. It is curated as a separate dismech entry, not as a subtype here.
  evidence:
  - reference: PMID:27521439
    reference_title: "Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The phenotypic spectrum varied from unspecified epilepsy (1), juvenile myoclonic epilepsy (2), photosensitive idiopathic generalized epilepsy (1), and generalized epilepsy with febrile seizures plus (1) to severe epileptic encephalopathies (11).
    explanation: >-
      Documents that juvenile myoclonic epilepsy and severe epileptic
      encephalopathy occur within the same GABRA1 allelic series, establishing
      the milder syndromes as differentials rather than subtypes.
- name: Childhood absence epilepsy (GABRA1 susceptibility)
  description: >-
    Childhood absence epilepsy is another idiopathic generalized epilepsy in
    which GABRA1 acts as a susceptibility gene alongside CACNA1H, GABRG2 and
    GABRB3. Absence seizures do occur within the GABRA1 encephalopathy spectrum,
    so the discriminator is the accompanying developmental impairment and seizure
    burden rather than the absence seizures themselves.
  evidence:
  - reference: PMID:26918889
    reference_title: "De novo GABRA1 mutations in Ohtahara and West syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GABRA1 mutations have been identified in patients with familial juvenile myoclonic epilepsy, sporadic childhood absence epilepsy, and idiopathic familial generalized epilepsy.
    explanation: >-
      Records childhood absence epilepsy as an established milder GABRA1-associated
      phenotype distinct from the encephalopathies.
- name: GABRB3-related developmental and epileptic encephalopathy (DEE43)
  description: >-
    The paralogous GABA-A receptor beta-3 subunit encephalopathy is
    mechanistically the closest neighbour: it too splits into gain-of-function
    and loss-of-function variant classes with the gain-of-function group more
    severely affected. Distinguishing them is a matter of which subunit gene
    carries the variant, and it matters because GABRB3 gain-of-function patients
    have a documented vigabatrin hypersensitivity that has no established GABRA1
    counterpart.
  evidence:
  - reference: PMID:37606373
    reference_title: "GABRA1-Related Disorders: From Genetic to Functional Pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Variants in GABRA1 have been associated with a broad epilepsy spectrum, ranging from genetic generalized epilepsies to developmental and epileptic encephalopathies.
    explanation: >-
      Frames GABRA1 as one of several GABA-A receptor subunit genes producing an
      allelic spectrum from generalized epilepsy to encephalopathy, of which
      GABRB3 is the closest paralogous neighbour.
  - reference: PMID:33585817
    reference_title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      When administered vigabatrin, these patients responded with reduced seizures but suffered severe adverse effects, such as decreased alertness, extreme drowsiness, hypotonia, sedation and respiratory difficulties, that reversed upon treatment cessation.
    explanation: >-
      Sources the vigabatrin-hypersensitivity claim to the study that reports it,
      quoting the clinical observation directly rather than the study's framing
      of its functional work. The GABRA1 paper cites this work but does not
      itself describe the hypersensitivity, so the claim cannot be quoted from
      there.
discussions:
- discussion_id: gabra1_models_lack_gof_encephalopathy_allele
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    Do the available Gabra1 mouse models actually model DEE19, given that both
    carry alleles from the mild end of the GABRA1 spectrum and both produce
    absence epilepsy rather than an infantile encephalopathy?
  rationale: >-
    Both committed animal models are informative for the shared network
    mechanism but neither reproduces the disease this entry curates. The
    heterozygous knockout models dosage loss, while most human DEE19 variants
    are missense; the A322D knock-in carries a juvenile myoclonic epilepsy allele
    from the opposite end of the severity spectrum. Neither models the
    gain-of-function transmembrane variants that produce the most severe human
    phenotype, and neither shows developmental regression or encephalopathy. The
    mismatch is mechanistically meaningful because the human genotype-phenotype
    data show severity is determined by variant class and structural position —
    exactly the dimension the existing models do not sample.
  attaches_to:
  - animal_models#Gabra1 heterozygous knockout mouse
  - animal_models#Gabra1 A322D knock-in mouse
  - pathophysiology#Gain-of-Function Shift in GABA Sensitivity and Desensitization
  proposed_experiments:
  - experiment_id: gabra1_gof_knockin_severity_comparison
    name: Knock-in mouse carrying a gain-of-function transmembrane-helix GABRA1 variant
    description: >-
      Generate a knock-in mouse carrying a human DEE19 gain-of-function
      transmembrane-helix variant (for example the TM3 A332V allele) and
      characterize seizure phenotype, developmental trajectory and EEG against
      both wild-type and the existing A322D line.
    would_support:
    - pathophysiology#Gain-of-Function Shift in GABA Sensitivity and Desensitization
    supporting_outcome:
    - >-
      The gain-of-function knock-in shows earlier seizure onset, a more severe
      and refractory seizure phenotype, and measurable developmental impairment
      relative to the A322D loss-of-function line, reproducing the human
      severity ordering.
    refuting_outcome:
    - >-
      The gain-of-function knock-in produces a phenotype no more severe than the
      A322D line, indicating that the human severity difference is not
      attributable to the receptor-level functional class alone.
notes: >-
  Scope and lumping decision. This entry is the severe, encephalopathic end of
  the GABRA1 allelic spectrum (DEE19 / OMIM EIEE19). The milder GABRA1 phenotypes
  are deliberately not modelled as has_subtypes here: juvenile myoclonic epilepsy
  and childhood absence epilepsy are established idiopathic generalized epilepsy
  syndromes with their own dismech entries, in which GABRA1 appears as one gene
  among several, and folding them in as severity grades of DEE19 would
  misrepresent both. They are recorded as differential_diagnoses instead. The
  within-entry heterogeneity that does matter — extracellular-domain
  loss-of-function versus pore-forming transmembrane gain-of-function — is
  captured as two genetic_context blocks and as a branch in the pathophysiology
  chain, because both classes cause the same encephalopathic disease by
  functionally opposite routes.

  Deep research provenance. This entry is backed by
  research/Developmental_And_Epileptic_Encephalopathy_19-deep-research-openscientist.md,
  produced through the repository's recorded provider-fallback path rather than
  by the assigned provider. falcon (Edison Scientific) returned HTTP 402 Payment
  Required — the account is out of credits — on a direct run and again under
  `--fallback`, which then selected openscientist; the report's frontmatter
  records that as fell_back, requested_provider and provider_attempts. Its
  reference validation is clean (23/23 resolved, confabulation_rate 0.0) and
  `just preflight-dr` against MONDO:0014328 passes with GABRA1 dominant, so
  there is no Named Entity Confusion. Its term validation carries
  needs_review: true, and the bindings it names are wrong in ways worth
  recording: NCIT:C935 is offered as "valproate" but is Vindesine Sulfate, and
  NCIT:C62735 as "ketogenic diet" but is Vaccine-Draining Lymph Node Lymphocyte
  Therapy. No CURIE was taken from the report. The entry's own evidence predates
  the report and was curated from primary literature fetched into
  references_cache, so every snippet here is an exact substring of a locally
  verified reference rather than copied from provider prose; the report was used
  afterwards as a cross-check and as the source of the vinpocetine lead.

  Quotation artifacts. Several snippets from PMID:37606373 are taken from the
  cached full text rather than the abstract, and the cached PDF extraction
  contains ligature and spacing artifacts ("coor dination", "identi ﬁed",
  "attention-de ﬁcit/"). These are preserved verbatim in the snippets because a
  snippet must be an exact substring of its source; they are not transcription
  errors introduced here. One consequence is that "prednisolone" cannot be
  quoted at all from the ACTH-response sentence, because the extraction splits
  it across a line-break hyphen; the drug is therefore carried in the treatment
  description and therapeutic_agent instead of in a snippet.

  Subunit spelling across sources. Snippets in this entry render the GABA-A
  alpha-1 subunit both as "alpha1" and as "α1". This is not an inconsistency
  introduced here: PMID:32047208 spells it "alpha1" in its own text while
  PMID:25447232 spells it "α1", and each snippet is an exact substring of the
  paper it cites. Normalizing either spelling would break exact-quote
  validation.

📚

References & Deep Research

References

7

PMID:37606373

GABRA1-Related Disorders: From Genetic to Functional Pathways.

No top-level findings curated for this source.

PMID:27521439

Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies.

No top-level findings curated for this source.

PMID:26918889

De novo GABRA1 mutations in Ohtahara and West syndromes.

No top-level findings curated for this source.

PMID:24623842

GABRA1 and STXBP1: novel genetic causes of Dravet syndrome.

No top-level findings curated for this source.

PMID:31707987

Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy.

No top-level findings curated for this source.

PMID:33585817

Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies.

No top-level findings curated for this source.

PMID:42227896

Add-on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss-of-function γ-aminobutyric acid type A receptor variants.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Record notes

Scope and lumping decision. This entry is the severe, encephalopathic end of the GABRA1 allelic spectrum (DEE19 / OMIM EIEE19). The milder GABRA1 phenotypes are deliberately not modelled as has_subtypes here: juvenile myoclonic epilepsy and childhood absence epilepsy are established idiopathic generalized epilepsy syndromes with their own dismech entries, in which GABRA1 appears as one gene among several, and folding them in as severity grades of DEE19 would misrepresent both. They are recorded as differential_diagnoses instead. The within-entry heterogeneity that does matter — extracellular-domain loss-of-function versus pore-forming transmembrane gain-of-function — is captured as two genetic_context blocks and as a branch in the pathophysiology chain, because both classes cause the same encephalopathic disease by functionally opposite routes. Deep research provenance. This entry is backed by research/Developmental_And_Epileptic_Encephalopathy_19-deep-research-openscientist.md, produced through the repository's recorded provider-fallback path rather than by the assigned provider. falcon (Edison Scientific) returned HTTP 402 Payment Required — the account is out of credits — on a direct run and again under `--fallback`, which then selected openscientist; the report's frontmatter records that as fell_back, requested_provider and provider_attempts. Its reference validation is clean (23/23 resolved, confabulation_rate 0.0) and `just preflight-dr` against MONDO:0014328 passes with GABRA1 dominant, so there is no Named Entity Confusion. Its term validation carries needs_review: true, and the bindings it names are wrong in ways worth recording: NCIT:C935 is offered as "valproate" but is Vindesine Sulfate, and NCIT:C62735 as "ketogenic diet" but is Vaccine-Draining Lymph Node Lymphocyte Therapy. No CURIE was taken from the report. The entry's own evidence predates the report and was curated from primary literature fetched into references_cache, so every snippet here is an exact substring of a locally verified reference rather than copied from provider prose; the report was used afterwards as a cross-check and as the source of the vinpocetine lead. Quotation artifacts. Several snippets from PMID:37606373 are taken from the cached full text rather than the abstract, and the cached PDF extraction contains ligature and spacing artifacts ("coor dination", "identi ﬁed", "attention-de ﬁcit/"). These are preserved verbatim in the snippets because a snippet must be an exact substring of its source; they are not transcription errors introduced here. One consequence is that "prednisolone" cannot be quoted at all from the ACTH-response sentence, because the extraction splits it across a line-break hyphen; the drug is therefore carried in the treatment description and therapeutic_agent instead of in a snippet. Subunit spelling across sources. Snippets in this entry render the GABA-A alpha-1 subunit both as "alpha1" and as "α1". This is not an inconsistency introduced here: PMID:32047208 spells it "alpha1" in its own text while PMID:25447232 spells it "α1", and each snippet is an exact substring of the paper it cites. Normalizing either spelling would break exact-quote validation.

Add OpenScientist deep-research report; add vinpocetine treatment; correct ADHD frequency-ranking claim · 2026-09-07T03:49:57Z · View source

Landed the deep-research artifact the entry previously lacked. falcon (Edison Scientific) was retried and still returns HTTP 402 (account out of credits), confirmed on a direct run; the repository's recorded --fallback path then selected openscientist, which produced research/Developmental_And_Epileptic_Encephalopathy_19-deep-research-openscientist.md (fell_back: true, requested_provider: falcon recorded in frontmatter). Report reference validation is clean (23/23 resolved, confabulation_rate 0.0, 19/23 on topic); just preflight-dr against MONDO:0014328 PASSES with GABRA1 dominant at 34 mentions and OMIM 615744 matching, so no Named Entity Confusion. The report's term_validation carries needs_review: true with four mislabelled CURIEs (NCIT:C935 offered as valproate is Vindesine Sulfate; NCIT:C62735 offered as ketogenic diet is Vaccine-Draining Lymph Node Lymphocyte Therapy; GO:0005783 and NCBITaxon:10116 mislabelled) and one obsolete term (GO:0005887); no CURIE was taken from the report. Content added from the report: a vinpocetine treatment (CHEBI:32297, therapeutic_modality SMALL_MOLECULE) targeting the loss-of-function arm, with three HUMAN_CLINICAL evidence items from PMID:42227896, including the GABRA1 Arg112Gln seizure-freedom result; the treatment is explicitly scoped as investigational and as inappropriate for the gain-of-function arm. Rewrote the stale 'Deep research provenance' paragraph in notes, which asserted no report backed the entry. Also corrected an overstatement found by an independent red-team review of the previously unreviewed commit 52d00f54: the entry claimed ADHD/behavioral disturbance was the most frequent neurodevelopmental accompaniment after developmental delay, but PMID:37606373 reports movement disorders at the identical 7/24 (29%), so the two are tied; corrected in both the phenotype description and the mirrored causal-edge description. Deliberately did not add the ERAD/proteostasis references the report surfaced (PMID:30481215, PMID:25406314): the cached full-text PDF extraction is heavily corrupted and the entry already covers the trafficking-rescue axis via verapamil. Validated with just validate, validate-terms, count-verified-snippets (71/71), the per-file and whole-KB gates, and validate-disorders.

Create: developmental and epileptic encephalopathy, 19 · 2026-09-06T00:33:29Z · View source

Created the DEE19 (GABRA1) entry from primary literature: 9 pathophysiology nodes forming a branched causal chain (GABRA1 variant -> loss-of-function current reduction with impaired trafficking, OR gain-of-function shift in GABA sensitivity -> impaired GABAergic inhibition -> E/I imbalance -> thalamocortical hypersynchrony -> seizure generation -> drug-resistant epilepsy with developmental impairment), 5 of which declare conforms_to against epilepsy_excitation_inhibition_imbalance; 11 HP-bound phenotypes; 2 genetic_context blocks capturing the extracellular-domain LoF vs pore-forming transmembrane GoF variant classes; 4 treatments; 2 animal models with modeled_mechanisms and readouts; 4 differentials positioning DEE19 at the severe end of the GABRA1 spectrum against the milder JME/CAE entries; one HUMAN_MODEL_MISMATCH discussion noting that both available Gabra1 mouse models carry mild-end alleles. 61 evidence items across 9 references, 61/61 snippets verified against locally fetched references_cache entries. DEEP RESEARCH FAILED: the assigned provider falcon (Edison Scientific) returned HTTP 402 Payment Required (account out of credits) on a direct run and again under just dr_fallback='--fallback'; the recorded fallback then selected claude_code, which failed with exit code 1. No other provider has credentials in this environment, so no deep-research report backs this entry and no preflight-dr or gene-drift check was possible; all content was instead curated from PubMed-identified primary literature fetched via just fetch-reference. Validation: just validate, validate-terms, count-verified-snippets (61/61), check-folded-hyphens, check-snippet-length, check-title-snippets, check-snippet-grading, check-duplicate-keys, check-entity-refs, check-causal-targets, check-qualifier-terms, check-enum-values, and the authoritative validate-disorders all pass. Branch was fast-forwarded 116 commits onto origin/main mid-session, which cleared two gate findings that were branch staleness rather than curation defects.

OpenScientist ▸

Developmental and Epileptic Encephalopathy 19 (DEE19) — Comprehensive Disease Report

openscientist-autonomous 23 citations 2026-09-07T03:07:58.176741

Developmental and Epileptic Encephalopathy 19 (DEE19) — Comprehensive Disease Report

Disease: Developmental and Epileptic Encephalopathy 19 (DEE19) MONDO: MONDO:0014328 | OMIM: 615744 | Causal gene: GABRA1 (HGNC:4075) Report type: Disease-level aggregation from primary literature and ontology/database knowledge (not individual EHR-derived).

Evidence-source key: [H] human clinical, [V] in vitro/heterologous expression, [M] model organism, [C] computational. Frequencies for rare, ultra-rare disorders are qualitative unless a cohort number is given. Where a claim reflects general DEE/GABAA biology rather than a DEE19-specific study, this is stated explicitly.

1. Disease Information

Overview. DEE19 is a rare, genetically determined developmental and epileptic encephalopathy caused by heterozygous, usually de novo, pathogenic variants in GABRA1, the gene encoding the α1 subunit of the type A γ-aminobutyric acid (GABA-A) receptor. It presents in infancy with multiple, frequently drug-resistant seizure types accompanied by developmental delay/intellectual disability. The term "developmental and epileptic encephalopathy" denotes that impairment arises both from the underlying genetic lesion acting on brain development (the developmental encephalopathy) and from the epileptic activity itself worsening function (the epileptic encephalopathy).

Key identifiers. - OMIM: 615744 (Developmental and epileptic encephalopathy 19; formerly "Epileptic encephalopathy, early infantile, 19 / EIEE19") - MONDO: MONDO:0014328 - Gene OMIM: GABRA1 137160 - Orphanet: within "Non-syndromic genetic developmental and epileptic encephalopathy" (ORPHA:442835) and the GABRA1-related epilepsy spectrum; DEE has no single unique ORPHA number for the 19 subtype. - ICD-10: G40.4 (Other generalized epilepsy and epileptic syndromes) / G40.83 (in some coding sets). ICD-11: 8A61 / 8A6Z (Developmental and epileptic encephalopathies). - MeSH: "Spasms, Infantile" / "Epileptic Syndromes" / "Epilepsy, Generalized" (no unique DEE19 MeSH; indexed under GABRA1 and epileptic encephalopathy). - HGNC: 4075; NCBI Gene: 2554; Ensembl: ENSG00000022355; UniProt: P14867 (GBRA1_HUMAN).

Synonyms / alternative names. Early infantile epileptic encephalopathy 19 (EIEE19); GABRA1-related epileptic encephalopathy; GABRA1-related developmental and epileptic encephalopathy; GABRA1 epilepsy. The GABRA1 allelic spectrum also includes juvenile myoclonic epilepsy (JME, OMIM 611136) and childhood absence epilepsy susceptibility.

Data provenance. Content here is aggregated at the disease level from primary case series, functional studies, mechanistic reviews, and curated databases (OMIM, ClinVar, HPO, Orphanet); it is not derived from a single patient EHR.

2. Etiology

Primary cause — genetic (monogenic, dominant). DEE19 is caused by pathogenic variants in GABRA1. The first GABRA1 epilepsy variant (p.Ala322Asp, A322D) was identified in a large French-Canadian JME family (Cossette et al. 2002 [H/V], PMID:11992121): "an Ala322Asp mutation in GABRA1, encoding the alpha1 subunit of the gamma-aminobutyric acid receptor subtype A (GABA(A)), is found in affected individuals of a large French Canadian family with juvenile myoclonic epilepsy." Severe encephalopathic phenotypes arise chiefly from de novo variants (Hernandez et al. 2019 [H/V], PMID:31056671): "two known GABRA1 mutations (c.335G>A, p.R112Q and c.343A>G, p.N115D) in six patients with intractable early onset epileptic encephalopathy."

Genetic risk factors. The causal variant itself is the risk factor. Most DEE19 variants are de novo dominant (see §9). No independent susceptibility loci or modifier genes are established for DEE19 specifically; general genetic-background modifiers are plausible but unproven.

Environmental risk factors. None established as causal. DEE19 is a monogenic disorder; environment does not initiate disease. General seizure-provoking factors (fever, sleep deprivation, missed medication, intercurrent illness) can precipitate seizures in an already-affected individual but are triggers, not causes.

Protective factors. No genetic protective alleles are defined. The only "protective" influence is functional: variants retaining greater residual GABA-A receptor function tend to produce milder phenotypes (Boßelmann et al. 2026 [H/C], PMID:42546502; GABRA3 paralog paradigm, Johannesen et al. 2026 [H/M], PMID:41289009). Effective early seizure control is the main modifiable protective factor against epileptic-encephalopathy worsening.

Gene–environment interactions. Not a major feature; disease is genetically determined. GxE is limited to environmental seizure triggers acting on the genetic substrate.

3. Phenotypes

DEE19 is clinically variable; the following are the characteristic features. HPO terms are suggested; frequencies are qualitative/cohort-based given rarity.

Core neurological phenotypes - Seizures, multiple types — the defining feature (obligate, ~100%). Types include generalized tonic-clonic, myoclonic, focal, atonic, absence, tonic, and epileptic spasms. HP:0001250 (Seizure), HP:0002133 (Status epilepticus), HP:0002123 (Generalized myoclonic seizure), HP:0002069 (Generalized tonic-clonic seizure), HP:0011153 (Focal-onset seizure), HP:0011097 (Epileptic spasm), HP:0002121 (Absence seizure). - Global developmental delay / intellectual disability (very frequent, ~most patients; severity mild→profound). HP:0001263 (Global developmental delay), HP:0001249 (Intellectual disability). - Developmental regression / stagnation with seizure onset (encephalopathy). HP:0002376 (Developmental regression). - Hypotonia (frequent). HP:0001252 (Hypotonia). - Ataxia / movement abnormalities / dystonia (subset). HP:0001251 (Ataxia), HP:0001332 (Dystonia). - Abnormal EEG — multifocal/generalized epileptiform discharges; hypsarrhythmia in those with spasms; sometimes photosensitivity. HP:0002353 (EEG abnormality), HP:0002521 (Hypsarrhythmia). - Speech/language impairment, absent or limited speech. HP:0002463 (Language impairment), HP:0001344 (Absent speech). - Behavioral features — autistic features, hyperactivity/ADHD-like behavior in a subset. HP:0000729 (Autistic behavior), HP:0000752 (Hyperactivity). - Microcephaly (subset, acquired or congenital). HP:0000252 (Microcephaly).

Onset: infantile, typically first months of life; in an 8-patient GABRA1 cohort onset was 3–8 months (Zhang & Liu 2022 [H], PMID:35937053): "Epilepsy onset age was between 3 and 8 months of age." Milder allelic phenotypes (JME) present in adolescence.

Severity/progression: variable severity (mild epilepsy → severe DEE); seizure course is often chronic and drug-resistant with an epileptic-encephalopathy plateau; developmental trajectory is impaired and largely static-to-slowly-progressive rather than neurodegenerative.

Quality-of-life impact: severe. Refractory seizures, intellectual disability, communication and motor impairment produce high dependency, need for caregiving, and reduced QoL for patient and family. No DEE19-specific EQ-5D/SF-36 data exist; QoL burden is inferred from severe DEE literature.

4. Genetic / Molecular Information

Causal gene. GABRA1 (HGNC:4075; NCBI Gene 2554; OMIM 137160; UniProt P14867), on chromosome 5q34, encoding the GABA-A receptor α1 subunit (a Cys-loop ligand-gated ion channel subunit with a large extracellular N-terminal GABA-binding domain and four transmembrane helices M1–M4; M2 lines the chloride pore).

Pathogenic variants. - Variant type/class: predominantly heterozygous missense variants; also nonsense/frameshift (haploinsufficiency) and splice variants. Reported pathogenic missense residues cluster in (i) the N-terminal GABA-binding domain (e.g., p.Arg112Gln/R112Q, p.Asn115Asp/N115D) and (ii) transmembrane domains (e.g., p.Pro260Ser/P260S, p.Leu296Ser/L296S, p.Trp315Leu/W315L, p.Ala322Asp/A322D) (Hernandez et al. 2019 [H/V], PMID:31056671; Krampfl et al. 2005 [V], PMID:16029191). "The α1(R112Q and N115R) subunit residue substitutions were in the N-terminal GABA binding domain." - Classification (ACMG/AMP): most recurrent DEE19 variants are Pathogenic/Likely pathogenic in ClinVar; PS2 (de novo), PM2 (absent from gnomAD), PS3 (functional studies), PP2 (missense-intolerant gene) commonly apply. VUS exist and benefit from functional/computational LoF-vs-GoF classification (Boßelmann et al. 2026 [H/C], PMID:42546502). - Allele frequency: pathogenic DEE19 variants are absent/ultra-rare in population databases (gnomAD); GABRA1 is highly constrained (high missense/LoF intolerance). - Somatic vs germline: germline (constitutional). De novo germline events dominate severe cases; parental germline mosaicism is possible (see §9). No somatic-mosaicism disease role established. - Functional consequence: predominantly loss-of-function (reduced surface expression, impaired biogenesis, reduced GABA sensitivity/gating), but a subset — particularly pore-lining M2 variants — are gain-of-function (Boßelmann 2026, PMID:42546502; paralog GABRA3, PMID:41289009). Dominant-negative effects on assembled receptors are described for some variants.

Modifier genes. None validated for DEE19. Genetic background likely contributes to variable expressivity.

Epigenetic information. No DEE19-specific DNA-methylation "episignature" is established. (Some other DEE genes have episignatures; GABRA1 is not a recognized episignature disorder to date.)

Chromosomal abnormalities. DEE19 is typically a single-nucleotide/small-indel disorder. Larger 5q34 deletions encompassing GABRA1 (contiguous GABRA1/GABRB2/GABRG2 cluster) can occur and are detectable by chromosomal microarray, but classic DEE19 is not a copy-number syndrome.

5. Environmental Information

Environmental factors: none causal. Not applicable as an etiology.
Lifestyle factors: not applicable to disease causation. Standard seizure hygiene (sleep, adherence) modulates seizure frequency.
Infectious agents: none. DEE19 is genetic, not infectious. (In differential diagnosis, acquired/infectious encephalopathies must be excluded — see §10.)

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

A heterozygous (usually de novo) pathogenic variant in GABRA1 alters the α1 subunit protein sequence. (demonstrated)
This leads to abnormal α1 subunit biogenesis: impaired folding, endoplasmic-reticulum retention, and excessive ER-associated degradation (ERAD) of the misfolded subunit at the expense of forward trafficking, reducing oligomerization/trafficking and cell-surface expression of α1-containing GABA-A receptors (Krampfl 2005 [V], PMID:16029191; Macdonald 2010 [V], PMID:20308251; Hernandez 2016 [V], PMID:27622563; for the archetype A322D, Fu 2018 [V], PMID:30481215: "the A322D mutation in the α1 subunit... causes its extensive misfolding and expedited degradation in the endoplasmic reticulum (ER)"). (demonstrated in vitro) — This ERAD/proteostasis defect is pharmacologically reversible (see §12), implicating GO:0036503 (ERAD pathway) and GO:0030968 (ER unfolded protein response).
In parallel, surface-expressed mutant receptors show reduced GABA-binding affinity and impaired channel gating (reduced current amplitude, altered activation/deactivation) (Krampfl 2005; Cossette 2002). Branch: rare M2/pore variants instead increase channel activity → gain-of-function (Boßelmann 2026 [H/C], PMID:42546502). (demonstrated)
Reduced/altered α1β2γ2 receptor function results in decreased fast phasic GABAergic inhibitory postsynaptic currents (reduced mIPSC amplitude/frequency) at inhibitory synapses (mouse VB thalamus, Zhou 2015 [M], PMID:25447232). (demonstrated in model; inferred in human)
Loss of inhibition leads to a cortical/thalamocortical excitation–inhibition imbalance and neuronal hyperexcitability, with disinhibition of thalamic relay nuclei promoting abnormal thalamocortical oscillations (Zhou 2015 [M]). (demonstrated in model)
Hyperexcitability results in recurrent, multifocal/generalized seizures (clinical). (demonstrated)
Because α1-GABA-A signaling also shapes early neurodevelopment (during the developmental period GABA is depolarizing/excitatory and guides proliferation, migration, differentiation, synaptogenesis; Stojanovic 2016 [H], PMID:26518133), receptor dysfunction during a critical infantile window — compounded by the deleterious effect of ongoing seizures on the developing network — leads to developmental delay/intellectual disability and encephalopathy (the "developmental" + "epileptic" encephalopathy). (partly inferred)
For gain-of-function variants, excess/altered GABAergic signaling similarly results in severe, treatment-resistant epilepsy and profound impairment, by analogy to the GABRA3 paralog paradigm (Johannesen 2026 [H/M], PMID:41289009). (inferred by paralogy)

Detail by category

Molecular pathways: GABAergic inhibitory neurotransmission via the ionotropic GABA-A receptor–chloride channel; no canonical growth-factor signaling cascade. GO:0007214 (GABA receptor signaling pathway); GO:1902476 (chloride transmembrane transport); Reactome "GABA A receptor activation."
Cellular processes: loss of fast synaptic inhibition; E/I imbalance; during development, altered neuronal proliferation/migration/synapse maturation (GO:0060078 regulation of postsynaptic membrane potential; GO:0007268 chemical synaptic transmission).
Protein dysfunction: misfolding, ER retention, impaired assembly/trafficking → reduced surface receptor; and/or altered ligand binding and gating. Loss-of-function predominant; gain-of-function and dominant-negative subsets.
Metabolic changes: none primary. (Ketogenic diet may help empirically via network effects, not a defined metabolic defect.)
Immune involvement: none; not autoimmune/inflammatory.
Tissue-damage mechanisms: not degenerative; injury is functional (network dysfunction) plus potential secondary excitotoxic effects of prolonged seizures/status epilepticus.
Biochemical abnormality: ligand-gated ion channel (chloride) dysfunction — a channelopathy of inhibitory neurotransmission.
Epigenetic changes: none established.
Molecular profiling: no disease-specific transcriptomic/proteomic/metabolomic signature; mechanistic data derive from heterologous electrophysiology, cryo-EM structure (α1β3γ2; Laverty 2019 [V], PMID:30602789), and mouse models.

Cell types (CL): GABAergic inhibitory interneuron (CL:0000617), neuron (CL:0000540), pyramidal/glutamatergic neuron (postsynaptic target; CL:0000598), thalamic relay neuron. Subcellular (GO CC): postsynaptic membrane GO:0045211; GABA-A receptor complex GO:1902711; integral component of plasma membrane GO:0005887; endoplasmic reticulum GO:0005783 (mislocalization site). CHEBI: GABA (CHEBI:16865), chloride (CHEBI:17996).

7. Anatomical Structures Affected

Organ / system: the brain and central nervous system (nervous system, UBERON:0001016). Primary organ: brain (UBERON:0000955); cerebral cortex (UBERON:0000956), thalamus (UBERON:0001897, thalamocortical circuits implicated by mouse data), hippocampus (UBERON:0002421), cerebellum (α1 highly expressed; UBERON:0002037). No primary involvement of non-neural organs; systemic effects are secondary to disability (e.g., feeding/respiratory complications).
Tissue/cell level: nervous tissue; GABAergic inhibitory synapses on cortical and thalamic neurons. Affected cell populations: inhibitory interneurons and their postsynaptic partners (CL:0000617 GABAergic neuron; CL:0000540 neuron).
Subcellular level: the inhibitory postsynaptic membrane (GO:0045211) and the GABA-A receptor–chloride channel complex (GO:1902711); with variant protein mislocalized to the endoplasmic reticulum (GO:0005783).
Localization / lateralization: bilateral, diffuse cortical involvement (generalized encephalopathy); EEG discharges may be generalized or multifocal. Not a focal/lateralized lesional disorder, though asymmetric epileptiform features can occur.

8. Temporal Development

Onset: congenital genetic lesion with clinical onset typically in infancy (first year, commonly 3–8 months) for DEE19; milder allelic phenotypes (JME) present in adolescence. Onset pattern: subacute/insidious emergence of seizures with developmental slowing.
Progression: chronic, lifelong. Seizures are frequently drug-resistant; course is often an early "stormy" phase followed by a plateau (epileptic-encephalopathy pattern). Not classically neurodegenerative; developmental impairment is largely static-to-slowly-evolving.
Course pattern: chronic with episodic seizure clusters and possible status epilepticus; some patients improve in seizure control over time while cognitive impairment persists.
Remission: true remission is uncommon in severe DEE19; seizure freedom is treatment-dependent and variable. Milder allelic phenotypes can be well-controlled.
Critical period: the infantile window of synaptic maturation is both the period of maximal vulnerability and the key window for early, effective seizure control and developmental intervention (rationale from developmental GABA biology, PMID:26518133).

9. Inheritance and Population

Epidemiology: DEE19 is an ultra-rare disorder; no precise prevalence/incidence figures are established (individual GABAA-DEE subtypes each account for a small fraction of DEEs). DEEs collectively affect on the order of ~1 in 2,000 children. GABRA1 is a recognized but minority cause among genetic DEEs.
Inheritance: autosomal dominant, most often de novo in severe DEE19; inherited autosomal-dominant transmission occurs for milder alleles (e.g., the A322D JME family, Cossette 2002, PMID:11992121).
Penetrance: high for severe de novo variants; incomplete/variable penetrance and expressivity for some inherited alleles (same variant can yield JME in one relative and more severe epilepsy in another).
Expressivity: highly variable — a hallmark of GABRA1 (mild IGE ↔ severe DEE), partly explained by variant functional class (LoF vs GoF; PMID:42546502).
Genetic anticipation: not applicable (not a repeat-expansion disorder).
Germline mosaicism: possible; recurrence in siblings of unaffected parents has been reported for DEE genes generally, warranting counseling.
Founder effects: the A322D JME variant is notable in a French-Canadian pedigree but is family-specific, not a population founder allele.
Consanguinity: not relevant (dominant mechanism).
Carrier frequency: not applicable (dominant, typically de novo; pathogenic alleles absent from population databases).
Population demographics: no ethnic predilection; reported worldwide. Sex ratio ~1:1 (autosomal; the 8-patient cohort was 4 male/4 female, PMID:35937053). Age distribution skews to pediatric onset.

10. Diagnostics

Genetic testing (definitive): exome or genome sequencing, or a multigene epilepsy/DEE panel including GABRA1, is the diagnostic mainstay; trio testing establishes de novo status. Single-gene GABRA1 testing is appropriate when the phenotype is highly suggestive. WES/WGS diagnostic yield in early-onset DEE is high (e.g., ~40–72% for onset <3 months; Thanuja & Kamate 2025 [H], PMID:40088508: "WES gave an overall yield of 61.9%... and 71.4%... in cases with epilepsy onset before three months."). Early genetic diagnosis frequently changes management (Elkhateeb 2024 [H], PMID:38221827; Esterhuizen 2023 [H], PMID:36480001).
Chromosomal microarray (CMA): to detect 5q34 deletions involving the GABRA cluster; usually normal in point-variant DEE19.
Karyotype/FISH/mtDNA/repeat-expansion testing: generally not informative; used to exclude alternative etiologies.
Variant interpretation: ACMG/AMP criteria; functional and computational LoF-vs-GoF classification refines VUS and guides therapy (PMID:42546502).
Electrophysiology: EEG is central — multifocal/generalized epileptiform discharges; hypsarrhythmia if spasms; used for seizure classification and monitoring.
Neuroimaging: brain MRI is typically normal or shows nonspecific findings (e.g., mild atrophy/delayed myelination); primarily excludes structural/malformative causes.
Laboratory/biomarkers: no specific blood/CSF biomarker; metabolic workup (including CSF neurotransmitters, lactate) is used to exclude treatable metabolic epilepsies. The genetic variant is the definitive molecular marker.
Clinical criteria: diagnosis follows the ILAE framework for developmental and epileptic encephalopathy (early-onset refractory seizures + developmental impairment) plus a confirmed pathogenic GABRA1 variant.
Differential diagnosis: other genetic DEEs — SCN1A (Dravet), KCNQ2, STXBP1, CDKL5, SCN2A, SCN8A, KCNT1, other GABAA genes (GABRB3, GABRG2, GABRB2, GABRA5); structural/metabolic/hypoxic-ischemic encephalopathies; pyridoxine-dependent epilepsy. Distinguished by gene testing and electroclinical pattern.
Screening: not part of newborn screening; cascade testing of relatives and prenatal/preimplantation testing available once the familial variant is known.

11. Outcome / Prognosis

Survival/mortality: no DEE19-specific survival figures. Severe DEEs carry elevated mortality including SUDEP and status epilepticus (Klein 2025 [H], PMID:40105713: "...refractory to treatment and to have high mortality rates."). Life expectancy is reduced in severely affected, non-ambulant, refractory patients; milder cases have near-normal survival.
Morbidity/function: high — intellectual disability, motor impairment, communication deficits, dependency; frequent comorbid autism/ADHD-like behavior. Long-term disability is the norm in severe cases.
Disease course/complications: drug-resistant epilepsy is common; DEEs show the highest drug-resistance rate among childhood epilepsy syndromes (77.7%) (Ayoub et al. 2024 [H], PMID:39150742). Complications: status epilepticus, injury from seizures, aspiration, feeding difficulty, SUDEP.
Recovery potential: limited for cognitive deficits; seizure control may improve with tailored therapy but developmental impairment usually persists.
Prognostic factors: earlier onset, multiple seizure types, myoclonus, and greater developmental delay predict drug resistance/poorer outcome (PMID:39150742). Variant functional class (GoF associated with more severe, treatment-resistant disease) is an emerging molecular prognostic marker (PMID:42546502, PMID:41289009).

12. Treatment

General principle: symptomatic seizure control plus developmental support; increasingly genotype-guided based on LoF vs GoF variant classification.

Pharmacotherapy (antiseizure medications, NCIT: Antiepileptic Agent): broad-spectrum ASMs are used empirically — valproate (NCIT:C935), levetiracetam, clobazam and other benzodiazepines (NCIT:C29075; GABA-A positive modulators), topiramate, lamotrigine, zonisamide, and for spasms vigabatrin/ACTH/corticosteroids. Cenobamate is a newer ASM with efficacy in refractory epilepsy/DEE (Klein 2025 [H], PMID:40105713). Because most DEE19 variants are LoF, drugs that enhance residual GABA-A function (benzodiazepines) are mechanistically rational; conversely, GABA-enhancing drugs may be counterproductive for GoF variants — underscoring functional classification.
Precision/personalized medicine: vinpocetine is an emerging targeted therapy for loss-of-function GABAA/GABRA1 DEE — adjunctive vinpocetine reduced seizure frequency and improved comorbidities in a case series of 9 patients with 8 GABAA-receptor variants (Gjerulfsen et al. 2026 [H/V], PMID:42227896): "Adjunctive vinpocetine shows promise as a targeted therapy for patients with GABA[A receptor variants]." LoF-vs-GoF prediction models directly inform drug selection (Boßelmann 2026 [H/C], PMID:42546502).
Non-pharmacologic: ketogenic diet (NCIT:C62735) is used empirically for refractory DEE; vagus nerve stimulation; epilepsy surgery is generally not applicable (non-lesional, generalized).
Advanced / experimental targeted therapeutics: For loss-of-function variants that impair receptor biogenesis/trafficking (e.g., A322D), proteostasis-modulating strategies rescue mutant surface expression and chloride current in cell models — the BiP/HSP70 activator BIX and modest activation of the ATF6/IRE1 unfolded-protein-response pathways (Fu 2018 [V], PMID:30481215), and VCP/p97 inhibition (Eeyarestatin I) plus the folding enhancer SAHA/vorinostat (Han 2015 [V], PMID:25406314). Ongoing work maps the GABAA proteostasis network to find drug-correctable variants (PMID:36030824, PMID:40112516, PMID:40161784, PMID:41178115). These are preclinical/experimental, not yet clinical. No approved gene therapy, ASO, or cell therapy for DEE19; conceptually attractive for a dominant channelopathy and under preclinical consideration.
Supportive/rehabilitative: physical, occupational, and speech therapy; developmental/educational support; nutritional and respiratory care; management of behavioral comorbidities.
Treatment outcomes/adverse events: response is variable and often partial; polytherapy is common; standard ASM adverse-event profiles apply (sedation, hepatotoxicity/valproate, behavioral effects/levetiracetam, visual-field effects/vigabatrin).
Strategy: individualized, guided by seizure type, EEG, and increasingly variant functional class; combination therapy is frequent in refractory disease.

13. Prevention

Primary prevention: not possible for de novo genetic disease. Genetic counseling for families with a known variant; prenatal diagnosis / preimplantation genetic testing (PGT) can prevent recurrence when a familial pathogenic variant is identified.
Secondary prevention: early genetic diagnosis enables early, targeted seizure control to mitigate epileptic-encephalopathy worsening (rationale: developmental critical period, PMID:26518133; value of early diagnosis, PMID:38221827).
Tertiary prevention: optimize seizure control to reduce status epilepticus and SUDEP risk; early developmental therapies; treat comorbidities.
Immunization / infectious control: not applicable (non-infectious); routine vaccination is encouraged as intercurrent illness/fever can trigger seizures.
Counseling: recurrence risk generally low for de novo cases but with a caveat for germline mosaicism; 50% transmission risk for an affected parent carrying a dominant allele.

14. Other Species / Natural Disease

Taxonomy / orthologs: GABRA1 is highly conserved across vertebrates. Mouse Gabra1 (NCBI Gene 14394; Mus musculus, NCBITaxon:10090); rat Gabra1 (NCBITaxon:10116); zebrafish gabra1 (Danio rerio, NCBITaxon:7955). Strong evolutionary conservation of the GABA-A receptor and its inhibitory function underlies cross-species modeling.
Natural disease in other species: no well-characterized naturally occurring GABRA1 epileptic-encephalopathy analog documented in companion animals (OMIA has no established GABRA1 DEE entry); GABAergic mechanisms are broadly implicated in animal seizure disorders. Veterinary relevance is chiefly as experimental models rather than spontaneous disease.
Comparative biology: the conserved role of α1-GABA-A receptors in fast inhibition means mechanistic findings translate across mammals; evolutionary conservation supports use of mouse/zebrafish models.
Transmission: not applicable (non-communicable genetic disease; no zoonotic potential).

15. Model Organisms

Mouse (Mus musculus, NCBITaxon:10090) — primary model. Heterozygous Gabra1 deletion produces absence seizures and reduced thalamic inhibition (Zhou et al. 2015 [M], PMID:25447232): "heterozygous deletion of Gabra1, the mouse homolog of the human absence epilepsy gene that encodes the GABAA receptor (GABAAR) α1 subunit, causes absence seizures." Demonstrates reduced synaptic α1, reduced mIPSC amplitude/frequency, ventrobasal-thalamus disinhibition, and partial cortical compensation (α3 upregulation). Knock-in of specific human variants and paralog GoF knock-ins (e.g., Gabra3^Q242L/+ showing increased seizure susceptibility, early death, cortical hyperexcitability; PMID:41289009 [M]) model genotype-specific mechanisms.
Model types available: knockout, heterozygous null, and knock-in (point-variant "humanized") mice; conditional alleles feasible via MGI/IMPC resources.
In vitro / cellular models: heterologous expression (HEK293, Xenopus oocytes) of recombinant α1β2/β3γ2 receptors for electrophysiology and trafficking assays (Cossette 2002; Krampfl 2005; Hernandez 2016) — the workhorse for LoF/GoF functional classification; patient-derived iPSC neurons are an emerging platform.
Phenotype recapitulation: mouse Gabra1 models reproduce seizures and reduced inhibition well; they capture the core channelopathy and network disinhibition.
Limitations: heterozygous-null mice model absence-type seizures better than the full severe human DEE19 encephalopathy; compensatory subunit upregulation and species differences in subunit expression limit full phenotype capture; cognitive/developmental phenotypes are only partially modeled.
Resources: MGI (mouse), ZFIN (zebrafish), RGD (rat), IMPC/IMSR for strains; Alliance of Genome Resources for orthology.

Summary of Findings, Supported and Refuted Hypotheses

Answer to the research question. DEE19 (OMIM 615744; MONDO:0014328) is a rare autosomal-dominant, usually de novo, developmental and epileptic encephalopathy caused by pathogenic variants in GABRA1 (GABA-A receptor α1 subunit). Variants impair fast GABAergic inhibition — predominantly by loss of function (defective receptor biogenesis, surface expression, GABA sensitivity, and gating), with a gain-of-function subset — producing cortical/thalamocortical excitation–inhibition imbalance that manifests as infantile-onset, often drug-resistant multi-type seizures with developmental delay/intellectual disability.

Supported hypotheses: (1) GABRA1 is the causal gene [strong: human genetics + functional data]; (2) loss-of-function/impaired inhibition is the dominant mechanism [strong: in vitro + mouse]; (3) variant functional class (LoF vs GoF) drives severity and treatment direction [emerging, strong]; (4) genotype-guided therapy (e.g., vinpocetine for LoF) is rational and clinically promising [emerging].

Refuted / not-applicable: environmental, infectious, autoimmune, metabolic, and epigenetic-episignature etiologies are not primary causes; DEE19 is a monogenic channelopathy.

Limitations & future directions. Precise epidemiology, natural-history/QoL metrics, and controlled treatment-outcome data specific to DEE19 are lacking; the pubmed corpus queried here was limited, so some claims lean on GABAA-DEE-wide and paralog evidence. Priorities: variant-specific functional maps (LoF vs GoF), prospective genotype-stratified trials (vinpocetine and GABA-A enhancers for LoF; caution/antagonism strategies for GoF), clinical translation of proteostasis-corrector approaches for biogenesis-defective variants (BiP/UPR modulators, VCP inhibition + HDAC inhibitors), iPSC/knock-in disease modeling, and development of allele-selective gene-based therapies (ASO/gene replacement) for this dominant channelopathy.

Key references (PMID)

11992121 — Cossette 2002, first GABRA1 (A322D) epilepsy variant.
16029191 — Krampfl 2005, A322D severe loss-of-function mechanisms.
20308251 — Macdonald 2010, GABAA subunit epilepsy mechanisms review.
27622563 — Hernandez 2016, GABR variant functional risk.
31056671 — Hernandez 2019, de novo GABRA1 in early-onset epileptic encephalopathy.
35937053 — Zhang & Liu 2022, GABRA1 pediatric cohort (onset 3–8 mo).
25447232 — Zhou 2015, Gabra1 mouse absence-seizure model.
26518133 — Stojanovic 2016, developmental α1 expression / excitatory GABA.
30602789 — Laverty 2019, cryo-EM α1β3γ2 structure.
42546502 — Boßelmann 2026, LoF/GoF prediction (505 individuals).
42227896 — Gjerulfsen 2026, vinpocetine precision therapy for LoF GABAA DEE.
41289009 — Johannesen 2026, GABRA3 paralog LoF/GoF paradigm.
30481215 — Fu 2018, ERAD/proteostasis rescue (BIX, ATF6/IRE1) of misfolded α1(A322D).
25406314 — Han 2015, VCP inhibition + SAHA restores trafficking-deficient α1(A322D).
36030824 / 40112516 / 40161784 / 41178115 — GABAA proteostasis network and correctors (experimental).
39150742 — Ayoub 2024, drug-resistance in DEE (77.7%).
40105713 — Klein 2025, refractory DEE, high mortality, cenobamate.
40088508 / 38221827 / 36480001 — WES yield & value of early genetic diagnosis in DEE.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	23
Resolved	23
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	23
On topic	19
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	50
Resolved	47
Unresolved (possible confabulation)	0
Obsolete	1
Unverifiable	2
Terms whose name was checked	30
Terms named correctly	20
Terms named as a different term	4
Terms whose name is worth a second look	6

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

GO:0005783 (2 mentions) - the report calls it "mislocalization site", "endoplasmic reticulum"; GO calls it endoplasmic reticulum
NCIT:C935 (1 mention) - the report calls it "valproate"; NCIT calls it Vindesine Sulfate
NCIT:C62735 (1 mention) - the report calls it "ketogenic diet", "Non-pharmacologic: ketogenic diet"; NCIT calls it Vaccine-Draining Lymph Node Lymphocyte Therapy
NCBITaxon:10116 (1 mention) - the report calls it "Gabra1"; NCBITaxon calls it Rattus norvegicus

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

GO:0005887 (GO_0005887) (1 mention) - replaced by GO:0005886

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

HP:0002069 (1 mention) - the report calls it "Generalized tonic-clonic seizure"; HP calls it Bilateral tonic-clonic seizure
HP:0011153 (1 mention) - the report calls it "Focal-onset seizure"; HP calls it Focal motor seizure
GO:0030968 (1 mention) - the report calls it "ER unfolded protein response"; GO calls it endoplasmic reticulum unfolded protein response, and lists "ER unfolded protein response" among its other names
GO:0007214 (1 mention) - the report calls it "GABA receptor signaling pathway"; GO calls it gamma-aminobutyric acid signaling pathway, and lists "GABA signaling pathway" among its other names
GO:0045211 (2 mentions) - the report calls it "inhibitory postsynaptic membrane", "Subcellular level: the inhibitory postsynaptic membrane"; GO calls it postsynaptic membrane
GO:1902711 (2 mentions) - the report calls it "GABA-A receptor–chloride channel complex"; GO calls it GABA-A receptor complex

Terms named inconsistently

The report gives these identifiers more than one name of its own:

ORPHA:442835 - called "Non-syndromic genetic developmental and epileptic encephalopathy", "Orphanet:** within "Non-syndromic genetic developmental and epileptic encephalopathy"
GO:0045211 - called "inhibitory postsynaptic membrane", "Subcellular level: the inhibitory postsynaptic membrane"
GO:0005783 - called "mislocalization site", "endoplasmic reticulum"
NCIT:C62735 - called "ketogenic diet", "Non-pharmacologic: ketogenic diet"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Developmental and Epileptic Encephalopathy 19 (DEE19) — Comprehensive Disease Report

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

Detail by category

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Summary of Findings, Supported and Refuted Hypotheses

Key references (PMID)

Artifacts

Reference Validation

Term Validation

Terms the report names something else

Obsolete terms

Terms whose name is worth a second look

Terms named inconsistently

Prefixes with no resolver